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ABSTRACT 
Hepatitis C (HCV) infects the liver, affecting its function, and may progress to liver 
cirrhosis and cancer. New direct-acting antiviral (DAA) treatments allow patients to achieve 
sustained virologic response (SVR) at higher rates than older, interferon-based treatments (PEG). 
Studies have shown DAAs are efficacious, but little research has been conducted to understand 
what patient characteristics contribute to receiving treatment, and the impact of SVR on 
healthcare resource utilization (HRU). Few studies have been conducted on how receiving 
treatment, and timing of treatment, impacts disease progression and long-term outcomes. 
I retrospectively identified 1,733 patients enrolled and tested for HCV+ at Kaiser 
Permanente Colorado between January 1, 2005 and December 31, 2015. Patients were required 
to have at least 12 months of enrollment prior to their first HCV RNA+ laboratory result for 
baseline, with no prior RNA+ labs or HCV antiviral treatment dispensing. Factors associated 
with receipt of treatment <=24 months following HCV+ date (through 12/31/2017) were 
identified. Likelihood of SVR and risk of HRU were measured <= 24 months following HCV+ 
dates. I forecasted the progression of HCV for four treatment strategies for HCV+ patients over 
multiple time horizons. 
Compared to Whites, African Americans were less likely to receive treatment. Compared 
to commercially insured patients, Medicaid recipients were less likely to receive treatment. 
Patients with DAA treatment achieved SVR sooner than patients on older treatments. Receiving 




likelihood of HRU. Measurable reductions in HCV-related disease outcomes were observed in 
earlier treatment strategies compared to the standard of care (SOC; treatment at advanced 
cirrhosis). Early treatment strategies improve life expectancy (total life years and QALYs) 
compared to SOC.  
Results suggest socioeconomic status may impact whether patients receive DAA 
treatment. DAAs significantly increase the likelihood of achieving SVR; SVR in turn reduces the 
likelihood of HRU. Finally, early treatment increases life expectancy and QALY life expectancy. 
Healthcare systems need to determine the value of curative therapies and how to pay for high up-
front costs for long-term benefits. More data is needed to measure impacts of DAA treatment on 
specific HCV disease outcomes.  
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Hepatitis C (HCV) is a virus that infects the liver and can affect liver function. HCV 
infection without intervention may progress to advanced liver fibrosis, decompensated cirrhosis, 
and cancer, all of which result in increased risk of death.1-4 HCV infects approximately 2.2% of 
the global population, most of whom are chronically infected.5 The CDC estimates there are 2.7-
3.9 million chronic cases of HCV in the United States as of 2012.4,6,7 New research suggests 
existing estimates of HCV underestimate the true prevalence of the disease.8,9 The 1945-1965 
“baby-boomer” birth cohort represents the largest population infected with HCV,2,8 presenting a 
significant disease burden for healthcare providers as these patients age into Medicare, and are 
often undiagnosed for HCV until adverse events arise.9 
The landscape for treatment of HCV has changed rapidly as new, orally-administered 
direct acting antiviral (DAA) medications have become available.5 Pegylated interferon-based 
therapies (PEG) were less costly but less effective, and had low tolerability among treated 
patients.10 Patients treated for HCV with PEG saw a 20-30% sustained virologic response (SVR; 
measure of HCV viral load post-treatment). PEG treatment was associated with a host of 
treatment intolerability issues, resulting in poor treatment adherence.  
Beginning in 2011 newer DAAs emerged, administered with PEG therapies (Telaprevir 
and Boceprevir; “triple-therapy” DAAs (TT)).5  SVR was achieved in 50-70% of patients treated 
with TT over 24-56 weeks, at a cost of $50,000-$80,000 for the entire regimen.11 Despite the 
higher cure rate, continued use of PEG with DAAs in TT led to continued treatment 
intolerability, a major reason for treatment non-adherence and discontinuation, making triple 




PEG-free regimens have since replaced triple-therapy treatments, beginning in 2013.13 
These new DAAs have transformed the management of HCV. Current DAA regimens saw over 
90% of patients achieve SVR in clinical trials; as well as achieve SVR over shorter treatment 
protocols (8-24 weeks, depending on disease severity). DAAs can be administered among 
patients with multiple chronic conditions.14,15  DAAs have become the standard of care for HCV 
antiviral treatment, replacing all PEG-related treatments for nearly all HCV genotypes. PEG-free 
DAAs have a higher cost than triple therapy, however, with wholesale acquisition costs (WAC) 
exceeding $100,000 for many DAA regimens.11,16  
Pan-genomic DAA treatments have emerged in the last few years, allowing for the 
treatment of patients with any genotype (the genetic markup of the virus) of HCV.17-20 The 
newest pan-genomic DAAs come at substantially lower WACs than older, predominantly 
genotype-1 DAAs.21,22 The emergence of pan-genomic DAAs has led to a paradigm shift in the 
approach for HCV care, from disease management and treatment to disease eradication.23-26 
Despite advances in treatment, HCV remains a significant public health concern. Health 
systems are often unsure of the size of their HCV patient population.9 Guidelines from the 
American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases 
Society of America (IDSA) recommend screening all baby boomers for HCV, in addition to 
continued screening of all patients with disease-related risk factors or exposures.2 Providers have 
been slow to adopt these guidelines in clinical practice, however, due to resource constraints.11,27-
30 Patients with HCV often remain undiagnosed until symptoms arise and, potentially, DAA 
treatment is ineffective.31,32   
It is unclear which patients receive DAA treatment and which patients do not, once HCV 
infection has been diagnosed.33 PEG-free DAAs have a higher tolerability and shorter treatment 




free DAAs is dependent more on patients’ access to care than underlying comorbid conditions.29 
Understanding which patients do and do not receive treatment, and the clinical and demographic 
factors that influence treatment, is important to determine where improvements to care can be 
made. 
Many cost effectiveness studies have shown reductions in HCV disease progression 
following DAA treatment.32,35-38 Less is known as to what extent DAAs impact healthcare 
resource utilization (HRU) post-treatment, and whether DAAs are effective in reducing HRU 
burden for health systems. HRU post-treatment may be a more important short-term measure of 
DAA effectiveness for health care systems and insurers than disease-related adverse outcomes 
(e.g. cirrhosis, liver transplant, liver cancer), as health systems may not retain patients long 
enough to experience reductions in disease-related adverse outcomes. Further, quantifying 
reductions in HRU as a result of achieving SVR can provide patient advocates and healthcare 
providers valuable evidence to improve access to care from health systems and insurers. 
Underestimated HCV prevalence, together with high costs of DAA treatment and limited 
real-world data on the effectiveness of reducing HRU and disease outcomes following treatment, 
leave healthcare providers, health care systems and insurers with limited resources to estimate 
disease burden among their patient populations and accurately predict expected outcomes and 
resource impact from treatment.  
Statement of Purpose 
The objectives of this dissertation are three-fold- 1) to identify factors that are associated 
with receiving HCV antiviral treatment; 2) estimate the likelihood of achieving SVR, as well as 
the risk of HRU, following HCV diagnosis; and 3) to model disease progression among patients 
diagnosed with HCV in clinical practice. In this dissertation, I construct a retrospective cohort of 




January 1, 2005 and December 31, 2015. I estimate the probability of receiving antiviral 
treatment among patients HCV+, comparing clinical and demographic characteristics that may 
influence the receipt of treatment. I examine the likelihood of treatment response (SVR) and 
HRU following HCV+. Finally, I project the difference in HCV disease progression outcomes 
for a hypothetical cohort of HCV+ patients, over five, 10 and 30-year time-horizons across 
different treatment strategies. The dissertation objectives will be addressed using three specific 
aims. 
Aims 
The goals of this dissertation are to describe the use of different HCV treatments and 
identify predictors of their use (Aim 1), and to assess treatment outcomes (SVR) and disease-
related healthcare resource utilization (HRU, defined as emergency department (ED) or inpatient 
(IP) encounters, a proxy for short term HCV-related outcomes) for patients receiving different 
treatment options (Aim 2). The information gained through Aims 1 and 2, as well as information 
from literature sources, is leveraged to estimate the reduction in disease progression for three 
different treatment scenarios through decision analysis modelling (Aim 3). Figure 1 depicts each 
specific aim as a question and how each aim flows into the next aim. 
 





Aim 1: Estimate the probability of receiving Hepatitis C (HCV) antiviral treatment among 
patients HCV+ between January 1, 2005 and December 31, 2015, comparing the differences in 
clinical and demographic characteristics of patients who did and did not receive treatment among 
those who tested HCV+ during the following treatment eras: 
1. Era 1: 2005-2010 (when peginterferon-based treatments (PEG) were available);  
2. Era 2: 2011-2013 (Era 2, when “triple therapy” (TT) treatments were available); and 
3. Era 3: 2014-2015 (Era 3, when PEG-free direct-acting antiviral (DAA) treatments were 
available).  
Hypothesis 1: Patients who received treatment are different, both clinically and 
demographically, from patients who did not receive treatment within each Era. 
Aim 2: Examine the differences in treatment response (sustained virologic response (SVR)); 
and healthcare resource utilization (HRU; any emergency department [ED] or inpatient stays 
[IP]) within 24 months following HCV+ diagnosis across treatment groups, from January 1, 
2005 through December 31, 2015. Aim 2 is divided into two sub-aims: 
2a) Compare the time to achieve SVR within 24 months of HCV diagnosis among patients 
that receive PEG treatment to patients that received DAA treatment and TT treatment. 
Hypothesis 2a: Patients who received DAA treatment have shorter time to SVR compared to 
patients who receive PEG treatment. 
2b) Compare the time to an HRU event within 24 months of HCV diagnosis among patients 
that achieve SVR and those who do not achieve SVR, controlling for whether or not patients 




Hypothesis 2b: Patients who achieve SVR have a shorter time to HRU compared to patients 
who do not achieve SVR. 
Aim 3: Project the difference in HCV disease progression outcomes (change in the 
proportion of patients progressing to cirrhosis, liver failure, liver transplant, cancer, and 
mortality) for a hypothetical cohort of HCV+ patients over five, 10 and 30-year time-horizons 
across four payer-based treatment strategies: 
1. Strategy 1: Advanced fibrosis, where patients receive DAA treatment if screened for F3-
F4 liver fibrosis (based on calculated Fib-4;39 current standard of care (SOC)); 
2. Strategy 2: “Moderate” fibrosis, where patients receive DAA treatment if screened for 
F2-F4 fibrosis;  
3. Strategy 3: “Minimal” fibrosis, where patients receive DAA treatment if screened for F1-
F4 fibrosis; and 
4. Strategy 4: Universal treatment, where all patients HCV+ receive DAA treatment, 
regardless of degree of liver fibrosis. 
Hypothesis 3: Treating patients earlier can reduce the proportion of patients 
experiencing HCV-related adverse outcomes. 
Significance 
This dissertation measures the impact of HCV therapies on HRU among a real-world 
HCV patient population across three eras of antiviral treatment (PEG, “triple therapy” and 
DAA). There have been many cost-effectiveness simulation studies highlighting the 
effectiveness of DAAs on the reduction of HCV disease progression compared to PEG 
treatments.4,32,35-37,40,41 These studies, however, are unable quantify actual disease progression 




of available follow-up data to measure disease progression for medium- and long-term outcomes. 
Moreover, there are few cost-effectiveness studies measuring changes in HRU following DAA 
treatment.32,42 Reducing HRU may be an attractive measure for health care systems and insurers 
to determine the short-term utility of broader DAA treatment access to patients. Finally, there is 
limited research on the impact of increasing access to DAA treatment on HCV disease 
progression in a managed care setting. 
Conceptual Framework 
The conceptual framework employed for this dissertation is based on the Behavioral 
Model for Access to Care (Aday and Andersen 1974).43 The Behavioral Model (figure 2) 
leverages health policy, health system and provider characteristics, as well as population(s) at 
risk, HRU and consumer satisfaction and patient outcomes in a hierarchical structure to describe 
and operationalize “access” to care. The Behavioral Model framework demonstrates how health 
care policy can affect health care delivery systems, providers and utilizers of healthcare. While 
other conceptual frameworks are structured to measure quality of care44 and managing care for 
patients with chronic conditions,45,46 the Behavioral Model is most appropriate for the goals of 
this dissertation which are to understand which patients are receiving treatment and which are 
not, and to what degree patient clinical and demographic characteristics influence access to care, 
disease progression and measurable outcomes. 
The Behavioral Model framework was developed to effectively build study designs that 
take health care access into account.47 From a methodological standpoint, it is important to 
consider factors that may influence access to care when measuring outcomes, particularly 
between heterogeneous patient populations and health care delivery systems. The behavioral 
Model has been adapted to address specific questions for particular patient groups, including 








Figure 2 Framework for the Study of Access to Care1 
1Aday LA, Andersen R. A framework for the study of access to medical care. Health Serv Res. 1974;9(3):208-220. 
 
At the patient level, predisposing factors can influence decisions regarding when and how 
to access health care, as well as the degree of engagement patients have with the health care 
system. For HCV in particular, the Behavioral Model framework yields a realistic structure of 
the current landscape of new, effective and expensive antiviral therapies that have entered the 




will be influenced both by policy requirements and statutes, and affordability of the therapies 
themselves.26,34,51 Patients will obtain access to care not only based on clinical characteristics 
(e.g. severity of infection/liver fibrosis, comorbid conditions), but also economic (e.g. 
affordability of care, insurance coverage) and social (e.g. willingness to adhere to treatment, 
environmental factors that would influence accessible care). Clinical effectiveness of these 
therapies has been presented in numerous clinical trials and cost-effectiveness studies; real-world 
effectiveness must take into account both the chronic nature of HCV infection among a growing 
and aging population at risk, limited resources of healthcare providers, and ever-increasing 
health utilization demands on healthcare delivery systems.  
Summary 
Aim 1 of this dissertation identifies what clinical and demographic characteristics are 
associated with receiving antiviral treatment.  Aim 2a estimates the likelihood of SVR among 
patients who receive antiviral treatment. Aim 2b estimates the risk of HRU among patients who 
do and do not achieve SVR. Aim 3 predicts disease progression under strategies that increase 
access to treatment.  
Results will inform health care systems and insurers on the impact treatment may have on 
broader health system utilization. This work will also aid policymakers, providers and health 
care researchers in understanding HCV patient characteristics in actual clinical practice and the 
impact of treatment on HCV disease progression. Understanding which patients receive 
treatment, as well as the clinical and demographic characteristics which may influence treatment, 
is important to address larger public health concerns of disease burden and treatment access, and 
to reduce health disparities across infected populations. Simulation modeling of HCV disease 
progression in Aim 3 will elucidate the impact of treating HCV at earlier stages of liver fibrosis 




insurers, policymakers and providers to ask when deciding the stage at which HCV treatment 
should be administered.  Simulating different HCV population-level treatment strategies of 
increasing treatment prescribing in earlier stages of liver fibrosis will provide a powerful tool for 
providers to measure the impact of modified treatment algorithms on HRU. The accumulation of 
this information will support the assessment of the effectiveness of HCV treatments and the 








REVIEW OF THE LITERATURE 
HCV Prevalence and Epidemiology 
Hepatitis C (HCV) is a virus which primarily affects the liver.2 HCV is the most common 
blood borne pathogen in the U.S.2,52,53 Infection is typically caused by exposure to infected 
blood, with blood transfusions and intravenous drug use the most common methods of 
infection.2,5,26  HCV was first identified in the late 1980s; testing of the U.S. blood supply began 
in 1992.2,54 Infection is asymptomatic, with disease progression occurring in only 15-30% of 
those infected.55,56 While estimates of disease prevalence in the U.S. vary between 2.9 million 
and 3.2 million infected adults (or approximately 1.3% of the population),2,54,55 recent research 
suggests the number of infected is larger than previously estimated.9 The majority of infected 
individuals do not have advanced stages of HCV and are often unware of their infection.2,8,54,57 
Approximately 80% of infected individuals do not clear the virus, however, making the risk of 
disease progression ever-present.2,56 Left untreated, HCV infection can lead to fibrosis (scarring) 
of the liver; decompensated cirrhosis and hepatocellular carcinoma (HCC), both major 
indications for liver transplantation, and mortality.5,6,9,58,59 HCV is also associated with other 
extrahepatic comorbid conditions.12,42,60 
There are six major genotypes of HCV, as well as several subtypes of the pathogen 
within genotypes.51,54 HCV genotypes vary by areas of the viral genome. Because HCV can 
replicate rapidly in an infected individual, the genetic code of the virus can change frequently, 
leading to variations of the virus.61,62 Viral mutations necessitate different pharmacological 
therapies to combat infection. Genotype 1 is the most common in the U.S. Approximately 75% 




of individuals are infected with genotypes 4-6 in the U.S.; although larger populations infected 
with genotypes 4-6 reside in parts of Africa and Asia.  
Individuals born in the Baby Boomer birth cohort (1945-1965) are disproportionately 
affected by HCV, the majority of whom were infected in the 1970-1980s when infection rates 
were highest and blood testing was unavailable.2,4,8,63 As the Baby Boomer cohort ages, HCV 
disease progression becomes more probable because the length of time they have been infected is 
longer, increasing the likelihood of advancing liver fibrosis and cirrhosis; indeed, the U.S. is 
experiencing a peak in HCV-related cirrhosis and HCC cases.4,64 Among incident HCV cases, 
the most affected populations are teens and adults participating in intravenous use of illicit 
drugs.2,50  
Diagnosis of HCV is confirmed through a series of laboratory tests, consisting of three 
stages: HCV surface antibody tests for HCV disease exposure, HCV RNA viral load testing (to 
assess current infection), and HCV genotyping, to determine the genotype of the 
pathogen.2,26,31,63 Figure 3 describes the care continuum of HCV at a national level in the U.S.65 
Among an estimated 3.5 million HCV-infected adults, roughly half have a diagnosis of HCV and 
are aware of their infected status. Only 27% have a confirmatory HCV RNA+ laboratory result; 
only 16% of patients HCV RNA+ go on to receive HCV antiviral treatment. Collectively, these 
gaps in care underscore the need for improved care management of HCV-infected populations, 
both in screening and treatment. Universal screening for all Baby Boomers, coupled with more 









Figure 3 – Schematic of the Hepatitis C Care Continuum1 
1 Yehia BR, Schranz AJ, Umscheid CA, Lo Re V, 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a 
systematic review and meta-analysis. PloS one. 2014;9(7):e101554. 
The advent of more efficacious treatment for HCV, coupled with an aging population, 
has led to a reevaluation of screening guidelines. In 2012, the Centers for Disease Control and 
Prevention (CDC) changed recommended screening guidelines to include universal cohort 
screening (e.g. all individuals born 1945-1965 should be screened for HCV);2 prior guidelines 
were risk factor-based screening, including age; current symptoms; history of liver disease; 






Changing Landscape of HCV Treatment 
The goal of all HCV treatments is sustained virologic response (SVR), currently defined 
as aviremia 12 weeks after completion of antiviral therapy (previously 24 weeks following 
antriviral therapy).66 SVR is measured specifically through an undetectable HCV RNA level 
using a sensitive assay (typically with a lower limit of 25 IU/mL) following treatment).67 
Achieving SVR has been shown to halt or reverse HCV-related disease progression.61,64,66,68,69 
While treatment efficacy has improved as treatment has evolved, the goal of treatment remains 
the same.  SVR achieved with earlier, interferon-based treatments is equivalent to SVR achieved 
with newer, more efficacious treatment.61,66,70 
Table 1 summarizes the landscape of HCV treatment from 2001-2017. HCV treatment in 
the early 2000s consisted of PEGylated interferon with ribavirin (PEG). PEG treatment consisted 
of boosting the body’s natural interferon receptors and genes to combat infection. The antiviral 
reaction could include blocking viral protein synthesis, inducing viral RNA mutagenesis and 
stimulate B cell proliferation and antibody production.62,70,71 PEG era treatments had an efficacy 
(SVR) of 30-50%. At that time SVR was measured 24 weeks following the end of a treatment 
regimen (SVR24). Patients on PEG era treatments often had poor adherence to treatment, due to 
the complexity and duration of the treatment (patients had to administer injections for 48-56 
weeks) and adverse treatment-related side effects of interferon.  These included:  nausea, 
influenza-like symptoms, anorexia, myalgia, pyrexia, arthralgia, hematologic toxicity (due to 
PEG alpha 2A), ophthalmologic disorders, and neuropsychiatric disorders such as insomnia, 
irritability, depression and (in rare cases) suicidality. 51,62,70 Adoption of more liberal screening 
practices, including universal screening to match CDC and U.S. Preventive Services Task Force 






 Table 1 – Overview of Hepatitis C (HCV) Antiviral Treatments 
 
1 Based on clinical trials. 




Evolution of Direct-Acting Antiviral Treatments 
The landscape for treatment of HCV has changed rapidly as new, direct acting antiviral 
(DAA) treatments became available, beginning in 2011. The common strengths of DAAs are 
their ability to prevent viral replication by binding to viral proteases (protease inhibitors, 
including NS3 protease, NS5A and NS5B polymerase).75 DAAs also inhibit the liver enzyme 
cytochrome P450-3A4 from metabolizing protease inhibitors, which in turn boosts the efficacy 
of other protease inhibitors (thus further limiting HCV viral replication).5,71,76 Incivek (telaprevir) 
and Victrelis (boceprevir), were the first DAA treatments approved by the FDA, and were used 
with peginterferon and ribavirin antivirals for treatment of HCV genotype 1 patients.77,78 While 
peginterferon bolsters patients’ immune response to HCV infection, Incivek and Victrelis hinder 
HCV’s ability to replicate. These triple-therapy (TT) treatments have resulted in 70% of patients 
achieving SVR24 in clinical trials.76,77,79-83 The use of TTs were problematic, however, due to 
increased treatment-related adverse events and toxicity.84-86 TTs were the effective standard of 
care of HCV through 2013. TT treatments have been discontinued since 2015, in the face of 
newer, more potent DAAs. 
The US Food and Drug Administration (FDA) has approved several new, PEG-free 
DAAs: Olysio (simeprevir-November 2013), a protease inhibitor similar to existing TTs; Sovaldi 
(sofosbuvir-December 2013), a drug that blocks the NS5B protein and hinders the replication of 
HCV and SVR at 12 weeks following end of treatment (SVR12) by over 90%87 in Phase III 
clinical trials;87-94 and Harvoni (ledipasvir and sofosbuvir-October 2014), an NS5A inhibitor, 
with approximately 90% SVR rates in Phase III clinical trials.15,53,95-100   
Viekira-Pak and Technivie are two four-part DAAs that entered the market for treatment of 
genotype 1 and genotype 4 patients, respectively.2,11,101 In addition to ombitasvir and paritaprevir 




pharmacokinetic enhancer when used in low dosage with other protease inhibitors); Viekira-Pak 
also uses Exviera (dasabuvir, an NS5B RNA polymerase) in place of ribavirin. 
Daklinza (daclatasvir) is another DAA that has received FDA approval for treatment of 
genotype 1 and 3 patients in combination with Sofosbuvir, and was the only NS5A inhibitor 
formulated to allow for dose adjustments to manage disease severity.102-107 Zepatier (elbasvir and 
grazoprevir) was approved by the FDA in January 2016 for the treatment of genotypes 1 and 4.20 
True pan-genomic DAA treatments have begun to emerge since 2016, beginning with 
Epclusa (sofosbuvir and velpatasvir) receiving FDA approval in October of 2016 for use for 
patients with any genotype 1-6.108-114 Vosevi (sofosbuvir, velpatasvir and voxilaprevir) and 
Mavyret (glecaprevir and pibrentasvir) receiving approval to treatment patients genotype 1-6 
with mild to moderate cirrhosis, as well as effective in patients with HIV or Hepatitis B 
coinfection.18,19 Pan-genomic treatments may permit broader access for treatment in the U.S. and 
globally as they reduce the complexity of HCV treatment limited to “special populations” of 
particular genotypes.113,115 The efficacy and effectiveness of HCV DAA era treatments has 
shifted the clinical practice of treating HCV from patient-level disease management to 
population-level disease control/eradication.61,66,116 
The Cost of Treatment 
DAAs are more effective at treating HCV than their historical PEG counterparts in 
clinical trials, but they come at a higher financial cost. Telaprevir and Boceprevir were estimated 
to cost $87,607-106,468 and $64,825-95,845 for 24-weeks of treatment regimens with 
peginterferon and ribavirin, respectively.76,94,117,118 PEG-free DAAs are estimated to cost 
between $66,000 to 100,000 or more for 12 weeks of treatment.11,34,78,94 Large insurers and 
provider networks have negotiated lower prices for DAA treatment for their respective 




manufacturers (AbbVie, Gilead Sciences and Merck & Co., Inc).11,73,94 Nevertheless, access to 
care remains an issue as costs of treatment remain a significant burden.25,119 
The challenges related to treatment access and affordability has been most highlighted 
among Medicaid patient populations.11,28 Since the advent of the DAA era, state Medicaid 
programs have struggled to meet the demand for treatment among patient populations with the 
highest prevalence of HCV.27 Costs of treatment led many Medicaid programs to limit DAAs 
only to patients exhibiting advanced stages of liver fibrosis; these limitations were the subject of 
several lawsuits by patient advocacy groups arguing patients were unjustly restricted from 
receiving life-saving treatments.28,29  
The Importance of a Cure 
Treatment efficacy is important because curing HCV significantly reduces the risk of 
liver disease progression. Cure virtually eliminates the risk of further disease progression, but 
complications of liver disease may remain (e.g. liver fibrosis progression may still continue). 
Studies have shown patients who achieve SVR experience reductions in liver fibrosis,26,62,69 as 
well as liver decomposition and cirrhosis (including jaundice, ascites, gastrointestinal bleeding, 
and hepatic encephalopathy).1,4,58 Reductions in liver fibrosis and cirrhosis in turn decrease the 
risk of hepatocellular carcinoma, liver transplants and mortality.1,4,64  
Reductions in adverse clinical outcomes were measured in the PEG era of antiviral 
treatment, when treatment duration exceeded 24 weeks, and adherence and tolerability to 
treatment was low. The implications of achieving SVR faster and with fewer treatment-related 
adverse events with DAA treatments suggests population-level HCV disease progression will fall 
dramatically.61,66 Efforts to enact policy for treating all patients with HCV are necessary and 
beneficial precisely because DAA treatment virtually guarantees cure, reducing disease 




decision tree analyses and simulations, that treated patient populations with HCV is cost-
effective both in life years gained and reduction of disease burden and costs of care.29,32,36-38,40,41 
Patient Disparities and HCV Treatment 
HCV patient populations are often faced with disparities that limit their access to care and 
treatment. Several studies have shown that, relative to the overall care-seeking population, HCV 
patient populations are often comprised of larger groups of older racial and ethnic minorities, 
Medicaid or other state-sponsored health insurance recipients, and those of a lower 
socioeconomic status who may not routinely seek care.8,50,120-122 Low socioeconomic status 
impacts both patients’ ability to access care (e.g. not receiving screening to confirm infection), 
treatment (direct costs of DAAs, as well as indirect costs associated with additional 
screenings/follow-ups that may require time off from work), and cure (lack of diagnosis allowing 
the potential for the liver disease to progress, complicating treatment).121,123,124 
 While efforts to improve patients’ ability to obtain HCV treatment have helped, the cost 
of treatment continues to foster barriers to care. At the beginning of the DAA era, only  patients 
exhibiting signs of disease progression  or with documented advanced liver fibrosis or 
compensated cirrhosis were authorized to received treatment 121,125 Restrictions set forth by 
health insurance providers limit who received treatment, requiring prior authorization for 
prescriptions in many health care settings.121 Prior authorization can include documented 
abstinence from drug and alcohol use, elevated METAVIR fibrosis scores and access to a 
gastrointestinal or infectious disease specialist, putting additional administrative burden on 
patients and providers.121 
Commercially-insured patients often have some degree of coverage for prescription 
drugs, though insurance copays may be prohibitive for many patients. Medicare covers some 




Advantage Prescription Drug plan. Medicaid reimbursement for HCV treatments puts an 
additional burden on providers to determine which treatments are approved and at what stage of 
disease progression.27-29  In one study, Medicaid insurance was significantly associated with high 
insurance denial rates for treatment with DAAs.126 Another study found Medicare and Medicaid 
dual coverage was associated with higher likelihood of receiving antiviral treatment than private 
insurance coverage, though it was conducted prior to prior authorization guidelines.127  
Large healthcare providers such as Medicaid and the Department of Veterans Affairs, 
while slow to adopt universal screening, have begun screening and treating more patients in 
tandem with negotiated lower drug pricing and legal mandates to treat, though not in every 
state.26,128 Patient advocacy groups such as the Fair Pricing Coalition (FPC) have worked closely 
with insurers and drug manufacturers to reduce to costs of HCV treatments for patients through 
patient-assistance programs for low-income patients and copayment reductions for patients 
carrying private insurance.21,129,130 These programs are not available nationwide, however, 
leaving providers and patients struggling to find the means to obtain treatment. 
Continued research and development of HCV antiviral drug treatments among 
manufacturers have fostered increased price competition, providing some cost relief for patients 
as newer treatments enter the market. In particular, pan-genomic DAAs are priced lower than 
older, genotype-specific DAA treatments, promising an opportunity for more infected patients to 
obtain treatment (see table 1).21,22  
Barriers to treatment must be alleviated to treat more patients and reduce the disease 
burden of HCV. Payers are slow to adopt treatments for reimbursement. Patients often do not 
have the means to cover the costs of treatment themselves, nor the ability to navigate the 
payer/insurance landscape to obtain assistance. Despite guidelines recommending increased 




patients), the costs of treatment have made accessing antiviral treatment difficult for many 
patients.  
Dissertation Significance 
This dissertation focuses on three important aspects of HCV treatment: 1) understanding 
which patients are receiving treatment and what characteristics (both clinical and demographic) 
may influence a patient’s likelihood to receiving treatment; 2) how treatments have changed in 
their efficacy and effectiveness in increasing SVR as well as impacting HRU in real-world 
patient populations; and 3) how changes in treatment strategies can impact patient outcomes. 
Examination of these aspects of HCV treatment is conducted through three specific aims 
highlighted in chapter 1 of this dissertation.  
Understanding which factors are most strongly associated with receipt of HCV antiviral 
treatment will elucidate where barriers to care exist. Treatment efficacy in clinical trials has been 
well-documented; less is known about real-world effectiveness on SVR achievement at 
population levels. Furthermore, there is no current research on the impacts of receiving treatment 
and achieving SVR on patient healthcare utilization, particularly emergency department and 
inpatient utilization among patients in a managed care setting. With the exception of Chidi et al. 
(2016) and Rattay et al. (2017), little research has been conducted on how changes in treatment 
strategies can impact future HCV disease progression. No studies have been conducted on DAA-
era HCV patient populations receiving treatments and disease outcomes in a commercially-
insured, integrated health system. Finally, no studies have been conducted comparing the 
probability of receiving treatment, treatment efficacy and healthcare utilization outcomes across 
and between treatment eras.  
Identifying HCV therapies in the context of real world prescribing is paramount to 




therapies should be adopted. The rapid changes in the treatment landscape have left many 
providers, insurers and health care systems struggling to determine which treatments to adopt 
and when, as well as which treatments to advocate for in reimbursement settings. Integrated 
healthcare systems need to understand which treatment(s) reduce near-term healthcare resources, 
and minimize the cost burden of DAAs.  
Understanding which patient populations are receiving treatment for HCV, as well as 
patients who are not receiving treatment and their underlying comorbid conditions, is important 
to address the larger public health concerns of the disease and lessen the health disparities across 
infected cohorts. Providers can be assisted with quantifiable data on what characteristics are most 
associated with receiving treatment (or not receiving treatment) in their care settings, whether the 
patient populations receiving treatment meet current screening guidelines and treatment 
recommendations, and where improvements to care can be made.  
Identifying treatment strategies is important to address larger public health concerns, 
including patient access, disease burden on health systems and overall population. Improved 
patient outcomes from receiving treatment before advanced stages of liver fibrosis, including life 
years gained and reductions in prevalence of cirrhosis, HCC, liver transplantation and mortality 
are important quantifiable evidence for patient advocates, health care providers, healthcare 








What factors are associated with receiving Hepatitis C (HCV) antiviral treatment, and 
what is the impact of receiving HCV antiviral treatment on sustained virologic response, 
healthcare resource utilization and disease progression among patients diagnosed with HCV in 
clinical practice? 
Data and Study Population 
Analyses for this dissertation are conducted using a retrospective cohort of patients 
diagnosed with HCV and enrolled in Kaiser Permanente Colorado (KPCO), an integrated health 
system providing care to patients in the Denver metropolitan area, as well the greater Colorado 
Front Range and Mountain regions, encompassing Adams, Arapahoe, Boulder, Broomfield, 
Denver, Douglas, El Paso, Jefferson, Summit and Weld counties. KPCO membership includes 
over 650,000 patients annually across a diverse population of commercially-insured, healthcare 
exchange and government-subsidized health care coverage programs. KPCO has one of the 
highest managed care enrollments of Medicare membership in Colorado, making its patient 
demographics ideal for studying HCV.  
Data for this dissertation were collected from KPCO’s Epic-based (EHR, a digital version 
of a patient’s medical chart131), as well as the Virtual Data Warehouse (VDW),132 a metadata 
relational database that captures 12 domains of patient utilization in their respective healthcare 
system, including demographics, utilization and encounters, enrollment and insurance coverage, 
drug fulfillment and claims, mortality and cause of death, laboratory lab results, and virtual 
tumor registry. The VDW provided rich EHR data for this dissertation, to identify the HCV 




fulfillment data. Moreover, the VDW allows for potential future scalability of this dissertation 
with other health systems sharing the VDW common data model across the broader Healthcare 
Systems Research Network (HCSRN).132,133 The VDW enabled me to compare the HCV patient 
population by different clinical and demographic characteristics, including age and gender, race 
and ethnicity, insurance coverage at index date and treatment exposure following index date, 
BMI and other comorbid conditions, and patient behavioral measures, including tobacco, alcohol 
and illicit drug use.  
This research was reviewed under the Colorado Multiple Institutions Review Board 
(COMIRB Protocol Number 15-0837), as well as the Kaiser Permanente Colorado Institutional 
Review Board (KP IRB # 1226054-9). 
Aim 1 Analysis Plan 
Aim 1 
Aim 1 estimated the probability of receiving HCV antiviral treatment among patients HCV+ 
between January 1, 2005 and December 31, 2015, comparing the differences in clinical and 
demographic characteristics of patients who did and did not receive treatment <= 24 months of 
patients’ first HCV RNA+ lab result during the following eras:  
1. Era 1: 2005-2010 (when peginterferon-based treatments (PEG) were available);  
2. Era 2: 2011-2013 (when “triple therapy” (TT) treatments were available); and 
3. Era 3: 2014-2015 (when PEG-free direct-acting antiviral (DAA) treatments were 
available).  
Aim 1 described characteristics of HCV+ patients during three eras of treatment availability 
and identified predictors of receiving treatment within each era following diagnosis (HCV 




dispensing <= 24 months following their first HCV+ date (index date). Aim 1 compared baseline 
(<=12 months prior index date) clinical and demographic characteristics among patients who do 
and do not receive treatment within each treatment era. The probability of receiving treatment 
was measured among patients in each treatment era. The hypothesis of aim 1 is that patients who 
received treatment during each era are different, both clinically and demographically, from 
patients who do not receive treatment. 
I constructed a longitudinal, retrospective cohort of patients diagnosed HCV+ (HCV 
RNA+) within KPCO between January 1, 2005 and December 31, 2015. I captured baseline 
clinical and demographic characteristics (up to one year prior to their first HCV+ diagnosis date 
(index date, beginning on 1/1/2004)) for these patients. I followed patients for up to 24 months 
following their index date, until receipt of HCV antiviral treatment (PEG, TT or DAA; defined 
as first prescription drug dispensing following their index date), end of available follow-up data, 
or the end of the follow-up period in the study (12/31/2017). Baseline clinical and demographic 
characteristics were compared between patients who do and do not receive follow-up treatment 
within each treatment era. I estimated the probability of receiving treatment among patients in 
the HCV study cohort within each treatment era. 
Study Design 
Aim 1 of this dissertation employed a retrospective cohort study design. Cohort designs are 
particularly useful to identify subsets of a population that are exposed and not exposed to a 
treatment intervention of interest over a defined observation period to compare differences in the 
probability of receiving treatment (Aim1 outcome) in the populations.134,135  Analyses for Aim 1 
were conducted using a retrospective cohort of patients diagnosed HCV+ (HCV RNA+ 




A baseline assessment period, index date and treatment exposure follow-up period (Aim 1 
outcome) were identified for all patients. Figure 4 (below) describes the study timeline for Aims 
1 and 2. Cohort entry was defined by each patient’s index date, expressed as the first HCV 
RNA+ lab test between 1/1/2005 and 12/31/2015. Patients could not have any HCV RNA+ lab 
tests prior to their index date (starting 1/1/2002 in EHR data availability at KPCO). Additionally, 
patients could not have any HCV antiviral treatment dispensing prior to their index date (starting 
1/1/2004 in EHR data availability at KPCO). Finally, patients must have been continuously 
enrolled (ignoring gaps of enrollment <= 30 days) in KPCO for at least 12 months prior to their 
index date to be included in the study.  
Primary Exposures and Outcomes 
A baseline period of 12 months prior to each patient’s index date was defined (i.e. starting at 
1/1/2004 for patients with index date of 1/1/2005), during which clinical and demographic 
patient characteristics were captured. The Aim 1 outcome, treatment exposure, was defined as a 
dichotomous variable for patients receiving an HCV antiviral treatment within 24 months of their 
index date. Specifically, receipt of follow-up treatment was defined as the first prescription 
dispensing within 24 months following index date, (i.e. until 12/31/2017 for patients with index 
date on 12/31/2015). The 24-month follow-up period was determined by the average treatment 
duration for treatment protocols available to patients during the study period (see table 1), as well 
as the availability of follow-up data for patients in each Era. Patients in Era 3 could only have a 
maximum of 24 months follow up (follow-up end date of 12/31/2017); thus patients in Eras 1 
and 2 were also limited to 24-months of follow-up. This limitation allowed patients in each era to 
have an equal opportunity to receive treatment (Aim1) and achieve SVR (Aims 2a and 2b) while 
not providing patients in earlier eras with additional follow-up time compared to patients in Era 




the goal of this dissertation is to quantify real-world likelihood of receiving treatment in the 
health system, including loss-to-follow-up/patient retention experienced at KPCO during the 
















Exposure for Aim 1 
Appendices A-F (Appendix) outline the variables, level of measurement and method of 
identification in the VDW that will be used for analyses in Aim 1. All variables were captured 
from each patient’s electronic health record (EHR) data. Enrollment start and end dates were 
captured from each patient’s record of enrollment in KPCO.  
Each patient included in the final HCV+ population had an index date, defined as their first 
HCV RNA+ laboratory result January 1, 2005 through December 31, 2015 with no prior HCV 
RNA+ lab results or antiviral prescription drug dispensing. Patients were stratified into one of 
three eras, depending on the year of their index date-  
1. Era 1: Patients diagnosed HCV+ January 1, 2005- December 31, 2010 (when 
peginterferon-based treatments (PEG) were available);  
2. Era 2: Patients diagnosed HCV+ January 1, 2011-December 31, 2013 (when “triple 
therapy” (TT) treatments were available); and  
3. Era 3: Patients diagnosed HCV+ January 1, 2014-December 31, 2015 (when PEG-free 
direct-acting antiviral (DAA) treatments were available). 
Laboratory results were captured from each patient’s EHR. HCV RNA positivity was defined 
by specific ranges of the HCV RNA assays performed during the study period. See appendix 
B (appendix) for a specific list of HCV RNA labs available in the KPCO EHR. 
Clinical and Demographic Characteristics for Aim 1 
Demographic and clinical characteristics were captured for all patients during the 
baseline period. Demographic characteristic included gender, race, ethnicity, age at index date, 
whether or not a patient was born in the 1946-1965 “baby boomer” birth cohort, and insurance 




Clinical characteristics included body-mass index (BMI), calculated liver fibrosis (Fib-4), 
depression, and comorbidity scores. International classification of Diseases, 9th and 10th Editions 
(ICD-9 and ICD-10, respectively), were used to identify specific comorbid conditions, including 
depression and obesity. Further, comorbid conditions identified during the 12-month baseline 
period were defined using the algorithms defined by Quan et al. (2005).136 For obesity, ICD-9 
codes 278.0x, v77.8, and 649.1; as well as ICD-10 codes E66.x (except for E66.3) were used to 
classify an individual with a diagnosis of obesity. Additionally, I used the most recent weight (in 
kilograms) measured during the baseline period, as well as most recent height in meters 
(measured at any point in the patient’s EHR, provided the patient was at least 18 years of age at 
the date of measure) to calculate a body-mass index (BMI, kg/m2). Patients with a calculated 
BMI>= 30 were classified as obese.  
To estimate liver fibrosis, I used the Fib-4 scoring algorithm.39 The Fib-4 calculation is 




where AST = aspartate aminotransferase; ALT = alanine aminotransferase. A value of > 3.25 has 
a positive predictive value of advanced fibrosis of 82%, with a specificity of 98% in confirming 
cirrhosis. Values 1.45-3.25 are not completely discernable for predicting liver fibrosis. 
Outcome for Aim 1 
 Receipt of HCV antiviral treatment (Aim 1 outcome) was defined by the first dispensing 
of any HCV antiviral treatment up to 24 months following index date. Appendices C-E list 
generic and brand names of PEG, “triple therapy” and DAA treatments included as Aim 1 
outcomes. Patients with any dispensing of an HCV treatment, regardless of drug class/type of 





Aim 1 analyses consisted of the following- 
1. Tabular summarization (descriptive statistics) of baseline clinical and demographic 
characteristics of patients HCV+ stratified by era of index date (Eras 1-3) and whether or 
not patients received treatment or not within 24 months following index date. Two-sided 
T-tests were used for comparison of continuous variables between patients who did and 
did not receive treatment <= 24 months following index date. Two-sided Chi-squared 
tests were used to compare dichotomous and categorical variables between patients who 
did and did not receive treatment <= 24 months following index date. The decision of 
whether to reject the null hypothesis for each test was assessed at alpha <0.05. 
2. Multivariate logistic regression model (for patients HCV+, model i below) to compare 
the probability of a patient HCV+ receiving follow-up treatment within each Era of 
treatment (Erai), controlling for baseline clinical and demographic characteristics of 
patients within each Era (Xi). The multivariate logistic regression model was adjusted for 
the following baseline covariates: era, age, gender, race, Quan score, calculated liver 
fibrosis (Fib-4), baseline obesity and depression. Model covariates were selected based 
on statistical significance in univariate models, clinical significance and other studies 
measuring treatment likelihood. 
i. 𝑙𝑛 HI(J,*+JK*LJMN*-I(J,*+JK*LJMOP)Q = 𝑓(𝐸𝑟𝑎U + 𝑋U + (𝐸𝑟𝑎U × 𝑋U)) 
The goal of Aim 1 is to identify what baseline clinical and demographic characteristics predict 
the probability of receiving treatment among patients HCV+ during each Era. The outcome of 
the model is whether or not a patient received treatment. I estimated the ratio of the probability 




1 estimated the odds of treatment exposure for patients HCV+ within each Era (1-3), controlling 
for baseline clinical and demographic characteristics of patients (Xi), including age, gender, race, 
ethnicity, insurance coverage, obesity, depression and Quan comorbidity score at baseline. 
Results were expressed as odds ratios by exponentiation of the parameter estimates of log linear 
function (i). T probability of rejecting the null hypothesis for testing the significance of odds 
ratios was assessed at alpha <0.05. Appendix F summarizes the presentation of Aim 1 outcome 
measures. 
Aim 1 Rationale  
It is unclear which patient populations are receiving antiviral treatments and which 
patients are not, and what factors are associated with receiving treatment. Further, few studies 
have studied factors associated with receiving treatment among a managed care patient 
population; to my knowledge none have been conducted among a managed care patient 
population in Colorado. Finally, no studies have been conducted to identify factors associated 
with receiving treatment across HCV treatment eras. 
Aim 1 used real-world data to assess associations between patient characteristics and 
receipt of treatment. Using simple statistical tests (Chi-squared for categorical variables; t-tests 
for continuous variables), I measured associations of baseline clinical and demographic 
characteristics between patients who do and do not receive treatment within treatment eras. 
Using logistic regression, I identified predictors of receipt of treatment from baseline clinical and 
demographic characteristics among patients within and across eras of treatment (Appendix F). 
Results from Aim 1 elucidate what factors influence receipt of treatment among patients during 




Aim 2 Analysis 
Aim 2 
Aim 2 examines the differences in treatment response (sustained virologic response (SVR); 
and healthcare resource utilization (HRU; any emergency department [ED] or inpatient stays 
[IP]) within 24 months following HCV+ diagnosis across treatment groups), in KPCO from 
January 1, 2005 through December 31, 2015.  
Using the study cohort defined in Aim 1, including patient’s index date and baseline 
covariates, I constructed a cohort of patients diagnosed HCV+ between January 1, 2005 and 
December 31, 2015 to model two specific outcome events-  
1. The time-to- SVR within 24 months of first HCV+ among patients that receive PEG 
treatment to patients that receive DAA or TT treatments; Aim 2a); and 
2.  The occurrence of HRU events within 24 months of first HCV+ among patients that 
achieve SVR to patients that do not achieve SVR, controlling for receipt of treatment 
(DAA, TT or PEG; Aim 2b). 
The study cohort design for aim 2 of this dissertation was event-based, where the events were 
SVR following patient’s first HCV+ date (index date; Aim 2a); and HRU within 24 months 
following a patient’s index date (Aim 2b). Figure 4 (above) describes the cohort inclusion and 
exclusion criteria for Aim 2. Baseline clinical and demographic characteristics identified in Aim 
1 were included as covariates to control for potential confounders in Aim 2 analyses. 
Study Design 
The cohorts in the aim 2 models were event-based. For Aim 2a, the outcome was SVR 
following the first HCV+ test result. For Aim 2b, the outcome was an HRU event following first 




outcome event. Patients were identified retrospectively from the KPCO VDW in the same 
manner as Aim 1. 
Baseline clinical and demographic characteristics identified in Aim 1 were included as 
covariates to control for potential confounders in the Aim 2 models. A categorical time-varying 
treatment exposure for each HCV antiviral treatment drug class (PEG, TT, DAA) was utilized in 
all Aim 2 models to incorporate the variability of time-on-treatment across drug classes, as well 
as differences in time between HCV+ test result and the start of an antiviral regimen. 
Additionally, incorporating time-varying covariates for treatment exposure reduced the risk of 
immortal time bias137,138 in the Aim 2 models.  
Measurement of Aim 2 Exposures and Baseline Characteristics 
Baseline clinical and demographic characteristics were captured and measured in the 
same manner as in Aim 1 (see appendices A-F for definitions). Treatment exposure types were 
defined by specific national drug code identifiers (NDCs) for PEG, “triple therapy” and DAA 
treatments (appendices C-E). Because HCV treatments are administered in combination with 
other medications (e.g. peginterferons with ribavirin; “triple therapy” with both peginterferon 
and ribavirin; and DAAs with and without ribavirin), treatment exposure type was defined by all 
HCV antiviral treatments dispensed to a patient within 14 days of the first of any of treatment 
dispensing. A time period of 14 days was chosen to account for polypharmacy onboarding of 
patients in some treatment protocols (particularly among “triple therapy” treatments) that began 
with one- to two-week prescribing of peginterferon before telaprevir or boceprevir.34,76,79,80,139 
Treatments were classified as follows- 
1. PEG Treatment Exposure Group - Peginterferon + Ribavirin dispensings within 14 
days of each other. 
 
2. “Triple Therapy” Treatment Exposure Group - Boceprevir + Peginterferon + 
Ribavirin dispensings within 14 days of each other; or Telaprevir + Peginterferon + 





3. DAA Treatment Exposure Group – Sofosbuvir; Simeprevir + Sofosbuvir; 
Ombitasvir + Paritaprevir + Ritonavir +Dasabuvir; or Ledipasvir + Sofosbuvir within 
14 days of each other. 
 
A categorical, time-varying treatment exposure (Aim 2 exposure) was defined by the first 
dispensing (if any) of any HCV antiviral treatment within 24 months following index date. 
Appendices C-E list generic and brand names of PEG, “triple therapy” and DAA treatments 
included as Aim 2 exposures. Patients with no treatment exposure were flagged as “0” for each 
month of available follow-up time until their first treatment exposure (or through the end of 
follow-up, event date, mortality/censoring during the 24-month follow-up period). Six patients 
were identified as having switched treatment regimens within the 24-month follow-up period and 
were subsequently dropped from these analyses. For patients with a treatment exposure during 
follow-up, the type of dispensing was captured such that patients with a PEG treatment exposure 
(appendix C) were flagged with a “1” in the first month and subsequent months of follow-up; 
patients with “triple therapy” were flagged as “2”; and patients with DAA exposure were flagged 
as “3”. Patients were flagged as having an exposure in the month of the dispensing date, as well 
as for all subsequent months following the dispensing date until an event (SVR or HRU for Aims 
2a and 2b, respectively), censor/loss to follow-up, death or end of 24-month follow-up period. 
Measurement of Outcomes in Aim 2 
Appendix F outlines the outcomes measures for Aims 2a and 2b. For Aim 2a, the 
outcome event was SVR post-index date within the 24-month follow-up period, defined by an 
HCV RNA- lab result. Negative lab results were defined by the specific lab assay for un-
detectable HCV RNA. For Aim 2b, HRU was defined as an emergency department or inpatient 




Immortal Time Bias 
The HCV study population in this dissertation was defined as treatment naïve (no antiviral 
drug dispensing prior to index date). To avoid introducing immortal time bias138 into the Aim 2 
models, where the start date of entry to the model incorrectly provides patients additional time 
where they cannot have experienced an event (“immortal” time; i.e. being unable to experience 
an event, such as not receiving treatment and thus being unable to achieve SVR), the index date 
was used as the start time in both aims 2a and 2b to reduce potential bias in favor of treatment 
exposure. In other words, patients entered the model at their first date of diagnosis and without a 
prior or current treatment exposure that may otherwise bias the outcomes of Aim 2a and 2b. 
Defining the study cohort in this manner, coupled with a time-varying covariate for treatment 
exposure (Aims 2a and 2b) and time-varying covariates for SVR attainment (Aim 2b) reduced 
the risk of immortal time bias137,138 in the Aim 2 models.  
Aim 2a Analysis Plan 
Aim 2 is divided into two sub-aims, beginning with Aim 2a, which estimates the likelihood of 
achieving cure following treatment-  
Aim 2a 
2a) Compare the time to achieve SVR within 24 months of HCV diagnosis among patients 
that receive PEG treatment to patients that received DAA treatment and TT treatment. 
Hypothesis 2a: Patients who received DAA treatment have a shorter time to SVR compared 
to patients who receive PEG treatment. 
I constructed a retrospective analytic cohort of patients to model the time to SVR within 




and demographic characteristics as well as time-varying treatment exposure for each HCV 
antiviral drug class (PEG, TT, and DAA).  
Exposure for Aim 2a 
The outcome in Aim 1 (treatment exposure within 24 months of index date) became the 
exposure variable for Aim 2a. Specifically, treatment exposure in Aim 2a was modeled as a 
time-varying covariate (measured in month-by-month intervals between index date and first 
treatment exposure date) to account for differences in when patients are diagnosed and 
subsequently treated. The time-varying treatment exposure variable was categorical (“1” for PEG 
drug class treatments; “2” for TT drug class treatments; “3” for DAA drug class treatments; “0” 
for no treatment), allowing for the model to control for the type of treatment exposure in addition 
to the timing of treatment exposure. All patients entered the model at t=0 in the “no treatment 
exposure” group, and only patients who subsequently received treatment at 0 < t £ 24 months are 
included in the analyses. Only patients who receive treatment may achieve SVR, thus only 
patients who received treatment after their respective index date were included in the model.  
Outcome for Aim 2a 
The outcome of interest in Aim 2a is time to SVR within 24 months of first HCV+ date 
(see Appendix F for specific labs). Patients were followed from first HCV+ date through first 
SVR (event); death, loss-to-follow-up (right-censored <24 months following index date); end of 
24-month follow-up; or the end of the study follow-up period (12/31/2017), whichever came 
first. 
Statistical Analysis for Aim 2a 
The model for Aim 2a was a Cox proportional hazards regression model with a categorical, 




within 24 months of HCV+ index date. I quantified the risk of SVR from the Cox model from 
the hazard ratios of achieving SVR for each time-varying treatment exposure drug class (e.g. the 
ratio of the hazard rate (instantaneous risk over time) in the DAA treatment exposure to PEG and 
TT exposures). Outcomes were time-to-SVR within 24 months of index date. Results were 
expressed as hazard ratios from parameter estimates of the proportional hazard function (ii).140 
i. ℎ(𝑡|𝑋U) = ℎZ(𝑡)𝑒[\](^) 
For the Aim 2a model, h0(t) the nonnegative baseline hazard function. Xi represents the 
covariate matrix for patient i, including baseline clinical and demographic characteristics, as well 
as time-varying treatment exposure for whether or not a patient has received treatment at time t. 
 
Aim 2b Analysis Plan 
The second sub-aim to Aim 2 estimates the risk of HRU in the HCV population-  
Aim 2b 
2b) Compare the time to an HRU event within 24 months of HCV diagnosis among patients 
that achieve SVR and those who do not achieve SVR, controlling for whether or not patients 
receive antiviral treatment. 
Hypothesis 2b: Patients who achieve SVR have a shorter time to HRU compared to patients 
who do not achieve SVR. 
Using the patient population defined in Aim 1, I constructed a study cohort of HCV+ 
patients who do and do not achieve SVR following index date to measure the hazard of HRU 
within 24 months of index date.  Aim 2b modeled the time-to-HRU adjusting for treatment 
exposure, for all patients HCV+ with and without treatment exposure, and again only among 




patients with and without treatment exposure provided a measurable risk estimate for all HCV+ 
who do and do not receive treatment and who do and do not achieve SVR. Modeling the risk of 
HRU for patients who received treatment provided a measurable risk estimate for patients across 
different treatment exposures and SVR attainments. 
Exposure for Aim 2b 
Like Aim 2a, I utilized a categorical time-varying covariate for any treatment exposures 
patients may experience during the 24-month follow-up period. Similarly to the time varying 
treatment exposure variable defined in Aim 2a, the time-varying SVR achievement variable was 
coded as “0” for each month of follow-up where a patient has not achieved SVR, and “1” for the 
month of SVR and all subsequent months following, until an event, censoring, or end of 24-
month follow-up period. 
Outcome for Aim 2b 
The outcome of interest in Aim 2b was occurrence of HRU events within 24 months of 
first HCV+ (index date). Patients were followed from first HCV+ date through any treatment 
exposure, achievement of SVR and HRU events within 24 months of index date, death, loss-to-
follow-up (right-censored <24 months following index date), end of 24-month follow-up, or the 
end of the study follow-up period (12/31/2017), whichever came first. 
Statistical Analysis of Aim 2b 
The model for Aim 2b utilized the Anderson-Gill proportional hazards model141-144 with 
counting process formulation for outcomes of interest (HRU). The model for Aim 2b included a 
time-varying covariate for SVR and a categorical, as well as a time-varying covariate for 
treatment exposure. The primary outcome for the Anderson-Gill model was the time to HRU 




estimated the hazard of HRU for the time-varying treatment exposure (e.g. the ratio of the hazard 
rate (instantaneous risk over time) in receiving treatment to not receiving treatment (or receiving 
a reference treatment)); SVR exposure (e.g. the ratio of the hazard rate for those who achieved 
SVR compared to those who did not achieve SVR); and baseline clinical and demographic 
characteristics. Outcomes were the occurrence of HRU events within 24 months of index date. 
Results were expressed as hazard ratios from parameter estimates of the proportional hazard 
function with intensity process (iii).140,141 
i. ℎU(𝑡) = ℎZ(𝑡)𝑒[\](J)𝑌U(𝑡) 
Where Xi(t) represents baseline clinical and demographic characteristics of patients, as well as 
time-varying treatment and SVR achievement, and Yi(t) the intensity process of whether or not 
an HRU event has occurred at time t. 
The Anderson-Gill model is a generalized Cox model and allows modeling of multiple 
HRU events, not simply a single HRU event or the first HRU event. The Anderson-Gill model 
allows for more robust risk estimates of HRU than the standard Cox model, accounting for the 
occurrence of recurrent HRU events while not allowing a patient’s prior event to impact the 
likelihood of a future event145.  
 
Aim 2 Rationale 
Estimating the probability of achieving SVR, controlling for baseline clinical and 
demographic characteristics and time-varying treatment exposure, allows for a real-world 
effectiveness measure to be estimated for the HCV patient population in CHORDS. RCTs and 
studies leveraging data from RCTs (comparative effectiveness meta-analyses, cost effectiveness 
and treatment simulation studies) have shown the effectiveness of DAA treatment over PEG 
treatment for curing HCV; however there has been limited research among real-world patient 




HRU as an outcome measure will yield an important estimate of patients’ utilization of 
the health care system. The cost-effectiveness of DAA treatment compared to PEG treatment has 
been shown in prior studies using RCTs; quantifying HRU using real-world patient utilization 
data will provide estimates for providers and health systems on the risk of increased system 
burden following diagnosis. Further, HRU provides an outcome measure than can be compared 
across HCV+ patients that do and do not receive treatment, allowing the impact of treatment and 
subsequent cure on near-term adverse events to be quantified in a large HCV+ patient 
population. 
Cox proportional hazard models for Aim 2 enable all patients meeting the cohort criteria 
to be included in the model for estimation of SVR and HRU, including patients who may be 
censored due to loss to follow-up prior to an outcome. All patients will be included at the time of 
cohort entry (index date) and are followed through treatment exposures (if any), SVR (if 
achieved), loss to follow up, censoring and subsequent outcomes through the end of the study 
period. 
Aim 3 Analytic Plan 
Aim 3 projects the difference in HCV disease progression outcomes (e.g. the change in the 
proportion of patients progressing to cirrhosis, liver failure, liver transplant, cancer, and 
mortality) for a hypothetical cohort of HCV+ patients, over five, 10 and 30-year time-horizons 
across four payer-based treatment strategies: 
1. Strategy 1: Advanced fibrosis, where patients receive DAA treatment if screened for F3-
F4 liver fibrosis (based on calculated Fib-4;39 current standard of care (SOC)); 
2. Strategy 2: “Moderate” fibrosis, where patients receive DAA treatment if screened for 




3. Strategy 3: “Minimal” fibrosis, where patients receive DAA treatment if screened for F1-
F4 fibrosis; and 
4. Strategy 4: Universal treatment, where all patients HCV+ receive DAA treatment, 
regardless of degree of liver fibrosis. 
Hypothesis 3: Treating patients earlier can reduce the proportion of patients 
experiencing HCV-related adverse outcomes. 
Aim 3 Method of Analysis 
I constructed a state-transition Markov model with cycle lengths of one year to estimate 
the impact of different treatment strategies on the HCV disease progression among a 
hypothetical cohort of HCV+, Genotype 1, treatment naïve patients receiving care in a managed 
care setting. I conducted sensitivity analyses, including varying mean age distributions, 
effectiveness measures, and disease progression transition probabilities, to assess the robustness 
of different strategies compared to each other. 
Model Structure and Assumptions 
Figure 5 (below) depicts the model structure for Aim 3. The Markov simulation model 
used in Aim 3 followed a similar structure to other Markov simulations of HCV treatment 
strategies and disease progression, including Chidi et al. (2016) and Rattay et al. (2017).29,40 
Patients begin distributed in one of five stages of liver fibrosis (F0-F4/Compensated Cirrhosis).39 
Each stage is defined as payer-based degrees of liver fibrosis and represent an approximation of 
liver fibrosis/cirrhosis among HCV patients at a population level (the gold standard being a liver 
biopsy). These strategies reflect how payers in the health system have defined treatment 
eligibility for HCV+ patients. The SOC strategy reflects all patients with advanced fibrosis 
(defined as patients F3 or above on their Fib-4 scores) may receive antiviral treatment; the 




receive antiviral treatment; minimal reflects patients F1 or above may receive antiviral treatment, 
and the Universal strategy reflects all patients who are HCV+ may receive treatment.  
Patients progress through HCV natural disease progression states; or receive DAA 
antiviral treatment intervention, with the possibility of liver fibrosis regression following 
treatment, and then HCV disease progression. Each treatment strategy modeled moved the 
treatment intervention to an earlier stage of liver fibrosis. Strategies 2-4 were compared to 
strategy 1 (SOC), as well as to each prior strategy (e.g. strategy 4 compared to strategies 2 and 3; 
strategy 3 compared to strategy 2).  
 




The input parameters for the Markov cohort simulation were obtained from multiple 
sources. Aim 3 input parameters were taken from the HCV population defined in Aims 1 and 2, 
including mean age of HCV+ patient population; proportions of patients achieving SVR during 
Era 3; risk-reduction effectiveness from treatment exposure (e.g. the change in SVR rates); and 
the most common DAA treatment regimen administered to patients at KPCO. 
The Markov model made the following assumptions- 
1. The model assumes a health system/payer perspective. 
2. The model assumed the patient population is currently enrolled at KCPO and thus 
patients were allocated to initial stages of liver fibrosis at t=0. 
3. Cycle lengths were one year. 
4. Time horizons were five-, 10- and 30-years following HCV+ diagnosis. 
5. All patients were considered treatment naïve (no prior HCV treatment exposure).  
6. All patients were considered HCV genotype 1. 
7. The mean and standard deviation of the age distribution of patients was obtained from 
estimates of the mean (standard deviation) age of patients HCV+ in Era 1 (identified in 
Aim 1). 
8. The standard of care (SOC) was patients receive treatment at advanced stages of liver 
fibrosis (Fib-4 scores F3-F4/Compensated Cirrhosis). 
9. Ledipasvir/Sofosbuvir (LDV/SOF) for a 12-week treatment duration was considered the 
HCV antiviral treatment SOC. This was the most common DAA treatment administered 
to patients HCV+ at KPCO 2015-2017. QALYs were based off this treatment regimen 




10. Treatment efficacy was defined as SVR achievement and is calculated from the hazard 
ratio of DAA compared to no treatment estimated in Aim 2a and transformed into a 
transition probability.  
11. All other transition probabilities for HCV disease progression were based on literature 
estimates.  
12. Patients could regress in liver fibrosis following antiviral treatment. 
13. Patients could progress through HCV natural history after achieving SVR at abbreviated 
rates; estimates of post-SVR disease progression are obtained from literature 
sources.32,37,38,40 
14. Patients could die at any stage in the model. 
15. Long-run disease progression outcomes (cirrhosis, liver failure, liver transplant, liver 
cancer, mortality) were considered priors for the simulation and were obtained from other 
literature-based sources, including other simulation models of HCV disease 
progression.29,32,37,40,41 
 Input parameters for the Markov simulation model of HCV treatment strategies are listed in 
table 10. Initial HCV patient characteristics (t=0) were obtained from the KPCO patient 
population (denoted as “calculated” under Reference/Source), otherwise from literature 
estimates. Uncertainty of estimates were derived from the percentage variation in estimates, 
as well as the confidence intervals from the estimates themselves. Transition probabilities for 
HCV (both natural disease progression and progression following achieving SVR), as well as 
quality-adjusted life years (QALYs), were calculated from literature estimates and other 
published HCV disease progression and/or cost-effectiveness simulation models. Because the 




(LDV/SOF) combination regimen is the only DAA treatment in the model as it is the most-
prescribed DAA prescribed to patients HCV+ at KPCO during the 2005-2015. 
 
Table 10 – Input Parameters for Markov Simulation Model 
Input Name Value Distribution Min1 Max1 
Reference/ 
Source 
Initial Probabilities of HCV Patient Cohort 
Average age of all patients at 
fist HCV+ date 
55.9 
Gamma 
40 70 Calculated 
Calculated Life Expectancy 81.3       146 
Probability of Direct-acting 
Antiviral (DAA) sustained 
virologic response (SVR), F0-
F4 
0.96 Beta 0.68 0.99 
Calculated 
and 29 
All-cause mortality prior to 
SVR (compared to non-HCV 
population) 
2.37 
      
147,148 
All-cause mortality post SVR 
(compared to non-HCV 
population) 
1.4 
      
147,148 
Proportion patients with 
Metavir2 score = F0 
0.17 Beta 0.15 0.19 149-151 
Proportion patients with 
Metavir2 score = F1 
0.35 Beta 0.32 0.39 149-151 
Proportion patients with 
Metavir2 score = F2 
0.22 Beta 0.2 0.24 149-151 
Proportion patients with 
Metavir2 score = F3 
0.14 Beta 0.13 0.15 149-151 
Proportion patients with 
Metavir2 score = F4 
0.12 Beta 0.11 0.13 149-151 
Proportion patients genotype 1a 0.65       152-154 
Cost discount rate 0.03       Calculated 
Outcome discount rate 0.03       Calculated 
1Uncertainty is derived from the percentage variation in the estimates and 95% confidence 
intervals of estimates. 
2 Metavir score (source: Cox-North et al 2018).166
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Table 10 (continued) – Input Parameters for Markov Simulation Model 
Input Name Value Distribution Min1 Max1 
Reference/ 
Source 
Disease Progression Transition Probabilities 
F0-F1 progression 0.12 Beta 0.11 0.13 29 
F1-F2 progression 0.12 Beta 0.11 0.13 29 
F2-F3 progression 0.12 Beta 0.11 0.13 29 
F3-F4 progression 0.12 Beta 0.09 0.14 29 
F3 to Decompensated Cirrhosis 0.01 Beta 0 0.03 60,149,150,155-158 
F4 to Decompensated Cirrhosis 0.04 Beta 0.01 0.04 60,149,150,155-158 




F4 to Hepatocellular Carcinoma 0.03 Beta 0.01 0.08 60,149,150,155-159 
F0 SVR to F1 0.001 Beta 0.002 0.01 60,149,150,155-159 
F1 SVR to F2 0.007 Beta 0.002 0.01 60,149,150,155-159 
F2 SVR to F3 0.003 Beta 0.002 0.01 60,149,150,155-159 
F3 SVR to F4 0.019 Beta 0.002 0.01 60,149,150,155-159 
F3 SVR to Decompensated 
Cirrhosis 
0.007 Beta 0.002 0.01 60,149,150,155-159 
F3 SVR to Hepatocellular 
Carcinoma 
0.007 Beta 0.006 0.008 60,149,150,155-159 
F4 SVR to Decompensated 
Cirrhosis 
0.007 Beta 0.002 0.01 60,149,150,155-159 






Decompensated Cirrhosis to 
Hepatocellular Carcinoma 
0.07 Beta 0.03 0.08 60,149,150,155-159 
Decompensated Cirrhosis to 
Liver Transplant 
0.03 Beta 0.02 0.06 60,149,150,155-159 






Decompensated Cirrhosis to 
Death 
0.1 Beta 0.04 0.13 60,149,150,155-159 
Hepatocellular Carcinoma to 
Death 
0.43 Beta 0.34 0.51 60,149,150,155-159 
Liver Transplant to Death after 
1 year 
0.14 Beta 0.06 0.42 60,149,150,155-159 
Liver Transplant to Death after 
2+ years 
0.03 Beta 0.02 0.11 60,149,150,155-159 
1Uncertainty is derived from the percentage variation in the estimates and 95% confidence 






Table 10 (continued) – Input Parameters for Markov Simulation Model 
Input Name Value Distribution Min1 Max1 
Reference/ 
Source 
Disease Regression Following SVR 
F1 regression to F0 0.5 Beta 0.25 0.82 115,160-162 
F2 regression to F1 0.5 Beta 0.25 0.82 115,160-162 
F3 regression to F2 0.5 Beta 0.25 0.82 115,160-162 
F4 regression to F3 0.34 Beta 0.19 0.49 115,160-162 
tF4SVRF2 0.08 Beta 0.06 0.1 115,160-162 
Utilities (QALYs)  
HVC F0  0.85 Beta 0.83 0.87 150,163-165 
HVC F1  0.85 Beta 0.83 0.87 150,163-165 
HVC F2  0.85 Beta 0.83 0.87 150,163-165 
HVC F3  0.79 Beta 0.77 0.81 150,163-165 
HVC F4  0.76 Beta 0.67 0.79 150,163-165 
Decompensated Cirrhosis 0.69 Beta 0.44 0.69 150,163-165 
Hepatocellular Carcinoma 0.67 Beta 0.6 0.72 150,163-165 
Liver Transplant after 1 year 0.5 Beta 0.3 0.8 150,163-165 
SVR after F0 0.92 Beta 0.9 0.94 150,163-165 
SVR after F1 0.92 Beta 0.9 0.94 150,163-165 
SVR after F2 0.92 Beta 0.9 0.94 150,163-165 
SVR after F3 0.86 Beta 0.81 0.85 150,163-165 
SVR after F4 0.83 Beta 0.81 0.85 Calculated  
Treatment QALYs 
Ledipasvir/Sofosbuvir F0 0.85 Beta 0.77 0.93 Calculated 
Ledipasvir/Sofosbuvir F1 0.85 Beta 0.77 0.93 Calculated 
Ledipasvir/Sofosbuvir F2 0.85 Beta 0.77 0.93 Calculated 
Ledipasvir/Sofosbuvir F3 0.79 Beta 0.72 0.86 Calculated 
Ledipasvir/Sofosbuvir F4 0.76 Beta 0.69 0.83 Calculated 
1Uncertainty is derived from the percentage variation in the estimates and 95% confidence 






The outcomes of the Markov model were the incremental effectiveness (IE) of strategies 
2, 3 and 4 compared to the SOC. Specifically, IE was calculated as the difference in the 
proportion of patients for each HCV disease progression state (e.g. decompensated cirrhosis, 
hepatocellular carcinoma, liver transplant and mortality), as well as total life years and quality-
adjusted life years (QALYs) between each strategy and the SOC. Additionally, IE was calculated 
between strategies and previous strategies for each HCV disease progression state.  
Deterministic results were used to determine a preferred strategy, defined as the strategy 
with the largest IE reduction in HCV disease progression states and increase in life years and 
QALYs gained. HCV disease progression outcomes were compared to the standard of care 
(SOC; treatment administered to HCV+ patients with advanced fibrosis [F3-F4]) and treatment 
strategies that treat patients at earlier stages of liver fibrosis. For each treatment strategy (SOC, 
F2-F4, F1-F4 and F0-F4 “Universal” Treatment), total life years, QALYs, and cumulative 
incidence of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and liver 
transplant (LT) were presented at five, 10 and 30-year time horizons. F2-F4, F1-F4 and F0-F4 
treatment strategies were compared incrementally to the SOC. Disease progression states, life 
years and QALYs were discounted at 3% annually.  
Sensitivity Analyses 
I conducted one-way sensitivity analyses, where a single input parameter is varied while 
other parameters are held constant to determine the impact of a given parameter on the IE of the 
preferred treatment strategy. I conducted Monte Carlo probabilistic sensitivity analyses in which 
all model inputs are simultaneously varied across 1,000 iterations to determine the likelihood of 




Model Validation Procedures 
The base case (no treatment exposure, natural disease progression) was used to validate 
the model against other literature estimates of HCV disease progression.55,167 Additionally, 
effectiveness measures of the SOC and subsequent strategies were compared to other cost 
effectiveness studies modeling similar treatment strategies, including Chidi et al. (2016) and 
Rattay et al. (2017).29,40 
Aim 3 Rationale 
Aim 3 of the dissertation addresses future disease progression of HCV in a real-world 
setting. It is unclear how effective DAA treatments are in a real-world HCV patient population, 
given the novelty of new DAA treatments and slow rates of disease progression for some 
medium and long-term outcomes (i.e. liver cancer). Moreover, despite recommendations from 
the AASLD to treat all patients screened positive for HCV,2 given the low rates of prescribing, it 
is unclear which patients are actually receiving DAA treatment, and at what stage of liver 
fibrosis treatment is most effective, given limited resources for treatment. Health care providers 
initially provided DAA treatment to patients suffering from advanced liver fibrosis (F3-F4 
advanced liver fibrosis and early stages of liver cirrhosis). Recently, patient advocacy and 
litigation has led providers to change treatment strategies and begin treatment at earlier, more 
minimal stages of liver fibrosis (F2-F3),168 or ignoring fibrosis stage as a factor for treatment 
altogether169. These changes may lead to a reduction in HCV disease progression (e.g. cirrhosis, 
liver failure, liver transplant, cancer and HCV-related mortality), but the magnitude of changing 
treatment strategies at the health system level remains unclear. 
A Markov simulation model of HCV disease progression amid different treatment 
strategies from a health care system perspective has important implications for treatment, and 




populations relied on data from randomized controlled trials (RCT) for transition probabilities 
for inputs and outputs, or used real-world, observational data for clinical inputs and/or transition 
probabilities but were built prior to the release of DAA treatments. Further, a Markov simulation 
model enables quantifiable projections of disease burden from changing HCV treatment policies, 
particularly among patients in Colorado. Models of HCV disease progression must account for 
the inherent variability of the infected population, diagnosis and screening, and crucially, which 
patients go on to receive drug treatment for HCV. Markov simulation models are suited for 
estimating long-term outcomes, diseases which require an array of possible transition states and 
outcomes, and when the timing of an event is important.  
Simulation modeling of HCV disease progression in Aim 3 will elucidate the impact of 
treating HCV at earlier stages of liver fibrosis on disease progression over a long-term time 
horizon, a crucial question for insurers and policymakers and providers to ask when deciding the 








Aim 1 Results 
Aim 1 estimates the probability of receiving HCV antiviral treatment among patients 
diagnosed HCV+ between January 1, 2005 and December 31, 2015, comparing the differences in 
clinical and demographic characteristics of patients who did and did not receive treatment within 
24 months of patients’ first HCV RNA+ lab result during the following eras:  
4. Era 1: 2005-2010 (when peginterferon-based treatments (PEG) were available);  
5. Era 2: 2011-2013 (when “triple therapy” (TT) treatments were available); and 
6. Era 3: 2014-2015 (when PEG-free direct-acting antiviral (DAA) treatments were 
available).  
 Figure 6 describes the selection criteria for identifying patients at Kaiser Permanente 
Colorado (KPCO) in the HCV analytic cohort. Approximately 1.1 million adult patients were 
enrolled at KPCO between January 1, 2005 and December 31, 2015, of which 34% were baby 
boomers (born 1945-1965). There were 3,494 patients identified as HCV antibody positive 
(Ab+); 3,409 had their first HCV RNA+ laboratory result (the clinical definition for HCV+) and 
had no prior HCV RNA+ results in their electronic health record (EHR). Additionally, 3,374 
(99% of HCV+) were treatment naïve, having no prior HCV antiviral prescription drug 
dispensing in their EHR. In the absence of knowing a true HCV infection date, or a history or 
testing/treatment for HCV at another healthcare provider, this population represented the incident 
HCV patient cohort for the dissertation, with the first HCV+ date representing each patient’s 






Figure 6 – Selection Criteria for Hepatitis C (HCV) Patient Population, 2005-2015 
 1,740 patients (52% of the incident HCV patient cohort) were continuously enrolled at 
KPCO for 12 months prior their first HCV + date (ignoring gaps of enrollment <= 30 days). 
1,733 patients had a calculable baseline Quan Comorbidity score136 (based on International 
Classification of Diseases, 9th and 10th editions diagnosis codes), representing 99% of patients 
continuously enrolled in KPCO and making up the analytic cohort for Aims 1 and 2.  
 Patients were stratified by the year of their first HCV+ date into eras of HCV antiviral 
therapy available. Among these patients, 999 (58%) had their first HCV+ date in treatment Era 1 
Adults >= 18 years of age January 1, 2005 - December 31, 2015
N = 1,071,263
Patients with >= 1 positive/detectable HCV Antibody (Ab+) lab result 2004-2015
n = 3,494 (0.3% of all adults)
Patients with >= 1 positive/detectable HCV RNA lab result (HCV+)
n = 3,409 (98% of Ab+)
Patients HCV+ 2005-2015 (no prior RNA+, HCV Antiviral Rx)
n = 3,374 (99% of all HCV+)
Patients continuously enrolled >= 12 months prior first HCV+ 
n = 1,740 (52% of HCV+)
Patients with a calculable baseline total Quan Comorbidity Score 
n=1,733 (analytic cohort, 99% of continuously-enrolled HCV+)
HCV+ 2005-2010 (Era 1)
n = 999 (58% of analytic cohort)
HCV+ 2011-2013 (Era 2)
n = 432 (25% of analytic cohort)
HCV+ 2014-2015 (Era 3)




(peginterferon [PEG] antiviral therapy), 432 (25%) in treatment Era 2 (Direct-acting antiviral 
[DAA] therapy with peginterferon; “Triple Therapy”), and 302 (17%) in treatment Era 3 (PEG-
free DAA therapy).  
 Table 2 describes the proportion of patients with HCV treatment exposure at any point 
following their index date and <= 24 months following their index date across treatment eras. A 
higher proportion of patients in Era 3 received treatment at any time after their index diagnosis 
compared to patients in Eras 1 and 2 (50% compared to 40% in Era 2 and 43% in Era 1; p=0.02). 
Patients in Era 3 received treatment sooner than patients in Eras 1 and 2 (mean (SD) difference 
between index date and first treatment dispensing date were 282.5 (259.4), 879.5 (612.1) and 
1,323.1 (1,313.3) days among patients in Eras 3, 2 and 1, respectively; p < 0.01). The proportion 
of patients receiving treatment <=24 months following their index date across Eras increased 
(47% in Era 3 compared to 16% and 21% in Eras 2 and 1, respectively; p<0.01). Mean (SD) 
difference between index date and first treatment dispensing date <= 24 months was significantly 
different across Eras (p<0.01), with 232.7 (189.8), 236.8 (213.9) and 169.8 (161.2) days 






Table 2 – First Treatment Exposure by Treatment Era 








HCV Antiviral Rx Treatment at any point following First HCV+ 
Patients Receiving following First HCV 








Mean (Std) Days Diff, 1st Rx Dispensing 








HCV Antiviral Rx Treatment within 24 months following First HCV+ 
Patients Receiving Rx following First HCV 








Mean (Std) Days Diff, 1st Rx Dispensing 








1 HCV+ patients 2014-2015 
2 HCV+ patients 2011-2013 
3 HCV+ patients 2005-2010 
4 Chi-squared tests were used for all categorical variables; F-test for all continuous variables. 
Comparing Clinical and Demographic Characteristics of Patients by Receipt of HCV Antiviral 
Treatment 
 Table 3 compares clinical and demographic characteristics between patients who received 
HCV antiviral therapy within 24 months of their index date and those who did not receive 
antiviral therapy within 24 months of their index date within each treatment Era. Patients in Eras 
1 and 2 who received treatment were significantly younger than patients who did not receive 
treatment (p<0.01). Patients in Era 3 who received treatment were significantly older (mean (SD) 
age of 58.5 (9.4) years) than patients who did not receive treatment (mean (SD) age of 53.3 
(13.7) years; p<0.01). Gender, race and ethnicity distributions were comparable between patients 
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1 Two-sided Chi-squared tests for all categorical variables; Two-sided T-tests for all continuous variables. 
2 The Fib4 calculation is used for predicting hepatic fibrosis or cirrhosis. The calculation is derived as: 𝐹𝐼𝐵4 =
`a*bcdefg	`hi(j/k)
Il+J*l*J	mPnLJ	?opqk D\	F`5i(3/5)
  (Source: Vallet-Pichard et al 2007). Abbreviations: AST = aspartate aminotransferase; 
ALT = alanine aminotransferase. A value of > 3.25 has a positive predictive value of advanced fibrosis of 82%, 
with a specificity of 98% in confirming cirrhosis. Values 1.45-3.25 are not completely discernable for predicting 
liver fibrosis. 
3 Based on the Quan comorbidity algorithm (Quan et al. 2005), calculated from available ICD9/10 diagnosis code 
data available <= 12 months prior HCV+ date (first HCV RNA+ laboratory result date). 
 
 
 A significantly higher (p<0.01) proportion of patients who received treatment in Eras 1 and 
2 had commercial, private pay or Medicare insurance coverage, compared to patients who did 
not receive treatment within these Eras. Among patients in Era 3, a lower proportion of patients 
with Medicaid insurance received treatment (7%) compared to the proportion of patients with 
Medicaid insurance who did not receive treatment (24%), though the differences were not 




KPCO health plan was not statistically different between patients who did and did not receive 
treatment within each Era.  
 In Era 3, a lower proportions of patients who received treatment presented for depression 
(16% compared to 35%, p=0.07). In Era 3, obesity was significantly more common among 
patients who did receive treatment (32%) than those who did not (21%; p = 0.02). Patients who 
received treatment had significantly lower (p<0.05) mean total Quan comorbidity scores 
compared to patients who did not receive treatment in each era. 
Factors Associated with Receiving HCV Antiviral Treatment 
 Adjusted odds ratios (OR) from logistic regression models of baseline clinical and 
demographic characteristics’ impacts on receipt of HCV antiviral treatment within each Era of 
diagnosis are presented in Table 4. Compared to white patients, the odds of receiving treatment 
were significantly lower for African American patients (OR 0.24, 95% CI [0.08, 0.72]; p<0.01) 
among Era 3 patients. Patients with Medicaid insurance coverage were significantly less likely to 
receive treatment compared to patients with commercial insurance (OR 0.36, 95% CI [0.16, 
0.82]; p<0.05) in Era 3. Patients in Era 3 with obesity were significantly more likely to receive 
treatment (OR 2.47, 95% CI [1.35, 4.53]; p<0.01). Higher baseline Quan comorbidity scores 
were associated with lower likelihood of receiving treatment in Era 3 (OR 0.85, 95% CI [0.76, 
0.96]; p<0.01). 
 Age was the only statistically significant baseline predictor of receiving treatment for 
patients in Era 2. Older patients were less likely to receive treatment during Era 2 (OR 0.95, 95% 
CI [0.9, 0.99]; p<0.05).  
 Among Era 1 patients, insurance status and comorbid conditions were significant predictors 




insurance coverage were less likely to receive treatment (OR 0.47, 95% CI [0.22, 0.99]; p<0.05). 
Higher baseline Quan comorbidity scores were associated with lower likelihood of receiving 
treatment in Era 1 (OR 0.86, 95% CI [0.79, 0.95]; p<0.01). 
 
Table 4 - Adjusted1 Odds Ratios (95% Confidence Intervals)2 of receiving Rx within 
Treatment Eras 








Age at 1st HCV+ Date       1.05 (1.02, 1.08)***    0.95 (0.9, 0.99)** 0.99 (0.97, 1.01) 
Baby Boomer (born 1945-1965) 1.26 (0.62, 2.52) 1.58 (0.52, 4.79) 1.16 (0.71, 1.88) 
Male (referent is Female) 0.78 (0.46, 1.32) 1.21 (0.67, 2.17) 0.85 (0.61, 1.17) 
Race (referent is White) 
African American     0.24 (0.08, 0.72)** 0.81 (0.31, 2.16)  0.92 (0.5, 1.68)  
Hispanic 1.17 (0.37, 3.74)  0.37 (0.1, 1.35)  1.37 (0.79, 2.37)  
Other Race 0.97 (0.55, 1.72)  0.53 (0.27, 1.04)  0.93 (0.65, 1.34)  
Insurance (referent is Commercial) 
Medicaid     0.36 (0.16, 0.82)** 0.94 (0.29, 2.99)  1.05 (0.4, 2.76)  
Medicare 0.97 (0.46, 2.06)  0.24 (0.05, 1.1)       0.47 (0.22, 0.99)** 
Other Insurance 2.59 (0.91, 7.43)  1.36 (0.41, 4.49)  0.73 (0.36, 1.5)  
Clinical Characteristics  
Depression (referent is No 
Depression) 
0.96 (0.44, 2.09)   0.96 (0.44, 2.09)   1.04 (0.68, 1.61)  
Obesity (referent is Not Obese)       2.47 (1.35, 4.53)*** 0.89 (0.49, 1.6) 1.18 (0.82, 1.7)  
FIB-4 Score 0.99 (0.87, 1.11)   1.05 (0.97, 1.14)  0.96 (0.9, 1.03)  
Quan Comorbidity Score       0.85 (0.76, 0.96)***  0.88 (0.76, 1.02)          0.86 (0.79, 0.95)*** 
1 Multivariate logistic regression, adjusting for era, age, gender, race, insurance status, Quan score, 
calculated liver fibrosis (Fib-4), baseline obesity (based ICD-9/10 and calculated BMI closest to HCV+ 
date) and depression (based on ICD-9/10 codes). 
2** and *** denotes significance at p<0.05 and p<0.01, respectively. 
Aim 2a Results 
Aim 2 examines the differences in treatment response (sustained virologic response 
(SVR)); and healthcare resource utilization (HRU; any emergency department (ED) or inpatient 
(IP) encounter) within 24 months following HCV+ diagnosis across treatment exposure groups, 
from January 1, 2005 through December 31, 2015. Aim 2a focused on treatment outcomes- 
2a) Compare the time to SVR within 24 months of HCV diagnosis among patients that 




 Table 5 presents summary statistics of the Aim 2a treatment exposure and outcome. 
Sustained virologic response (SVR, HCV RNA- lab result following HCV antiviral treatment) 
<= 24 months following HCV+ date is stratified by available treatment exposure groups (PEG, 
“Triple Therapy” and DAA). 424 patients were identified as having received treatment <= 24 
months following diagnosis. Across different treatment exposure groups, less than half of 
patients HCV+ went on to receive HCV antiviral treatment (47%, 16% and 21% for DAA, 
“Triple Therapy” and PEG treatment exposure groups, respectively (p<0.01)). The proportion of 
patients achieving SVR is 77%, 71% and 53% for DAA, “Triple Therapy” and PEG treatment 
exposure groups, respectively (p<0.01).  
Table 5 – Treatment Exposure and Sustained Virologic Response (SVR) <= 24 months following 












Patients Receiving Antiviral Rx 








Patients Achieving SVR (% of 








1 HCV+ patients 2014-2015, when Direct-Acting Antiviral (DAA) treatment regimens were available 
2 HCV+ patients 2011-2013, when “Triple Therapy” treatment regimens were available 
3 HCV+ 2005-2010, when Peginterferon (PEG) treatment regimens were available 
4 Chi-squared tests were used for categorical variables; F-tests for continuous variables. 
 
Time to SVR Following HCV+ 
 Table 6 summarizes the results of the unadjusted Cox proportional hazards model for the 
time to SVR with time-varying treatment exposure among patients with HCV antiviral treatment 
exposure. The unadjusted model is used to calculate the hazard ratio (HR) for time-varying 
treatment exposure drug class (DAA and “Triple Therapy”, with PEG-class treatment exposures 




Table 6 – Unadjusted Cox Proportional Hazards Model of time to Sustained Virologic Response 
(SVR) <=24 months following first HCV+ date among patients receiving HCV antiviral 
treatment (n=424), with Time-varying Treatment exposure  
 
Hazard Ratio (HR) 
(95% CI)  
n = 424 p-value Sig1 
Time-Varying Treatment Exposure (referent is PEG Rx Exposure) 
Time-varying DAA Rx exposure 2.19 (1.72, 2.81) <0.01 *** 
Time-varying “Triple Therapy” Rx exposure 0.97 (0.64, 1.46) 0.87  
1 ** and *** denotes significance at p<0.05 and p<0.01, respectively.  
 Patients exposed to DAA treatments achieve SVR at nearly twice the rate of patients 
exposed to PEG treatments (HR 2.19; 95% CI (1.72, 2.81); (p<0.01). There was no statistically 
significant difference between the likelihood of achieving SVR among patients receiving “Triple 
Therapy” treatments compared to PEG treatments (p=0.87). 
 Figure 7 graphs the cumulative probability plot of SVR attainment <= 24 months of HCV+ 
date. Patients who received DAA treatment achieved SVR at a faster rate than patients who 
received “Triple Therapy” or PEG treatments. After 12 months, approximately 60% of patients 
who received DAA treatment had not yet achieved SVR, compared to approximately 90% of 
patients who received “Triple Therapy” or PEG treatments. At 24 months, < 10% of patients 
who received DAA treatment had not achieved SVR, compared to approximately 25% of 






Figure 7 – Cumulative Survival Probability Plot of Achieving SVR <= 24 months following first 
HCV+ date among Patients Receiving HCV Antiviral Treatment (Patients HCV+ with Treatment 
Exposure; n=424) 
 
 Table 7 summarizes the results of the adjusted Cox proportional hazards model for the 
likelihood of achieving SVR with time-varying treatment exposure among patients with HCV 
antiviral treatment exposure. Similar to the unadjusted model, the primary exposure in the 
adjusted Cox model is the time-varying treatment exposure drug class (DAA and “Triple 
Therapy”, with PEG-class treatment exposures as the reference group). The adjusted model also 
includes baseline categorical and continuous variables from Aim 1 analyses.   
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Table 7 – Adjusted Cox Proportional Hazards Model of time to Sustained Virologic Response 
(SVR) <=24 months following first HCV+ date among patients receiving HCV antiviral 
treatment (n=424), with time-varying Treatment exposure  
 
Hazard Ratio (HR) (95% CI) 
n = 424  p-value Sig1 
Time-Varying Treatment Exposure (PEG is Referent) 
Time-varying DAA Rx exposure 2.24 (1.69, 2.97) <0.01 *** 
Time-varying “Triple Therapy” Rx exposure 1.02 (0.60, 1.73) 0.95  
Age/Gender 
Age at First HCV+ Date 0.99 (0.98, 1.01) 0.51  
Baby Boomer (Non-Baby Boomer is referent) 0.84 (0.56, 1.24) 0.38  
Male (Female is Referent) 1.15 (0.89, 1.49) 0.28  
No. Years Enrolled Prior to First HCV+ Date 1.01 (0.96, 1.07) 0.70  
Race/Ethnicity (referent is White) 
African American 0.54 (0.30, 0.98) 0.04 ** 
Hispanic 0.88 (0.55, 1.39) 0.57  
Other 0.93 (0.69, 1.24) 0.60  
Insurance Status at First HCV+ Date (referent is Commercial Insurance) 
Medicaid 0.78 (0.43, 1.41) 0.41  
Medicare 0.92 (0.57, 1.48) 0.73  
Other Insurance 1.7 (1.08, 2.69) 0.02 ** 
Baseline (<=12 Months prior to First HCV+ Date) Clinical Characteristics 
FIB-4 Score 0.96 (0.91, 1.03) 0.27  
Obesity (non-obese is referent) 1.02 (0.76, 1.37) 0.89  
Depression 0.76 (0.52, 1.11) 0.15  
Baseline Total Quan Score 1.04 (0.97, 1.12) 0.30  
1 ** and *** denotes significance at p<0.05 and p<0.01, respectively.  
 In the adjusted Cox model, the hazard for SVR in patients exposed to DAA treatments is 
nearly double that of patients exposed to PEG treatments (HR 2.24; 95% CI (1.69, 2.97); 
(p<0.01)). There was no statistically significant difference between the hazard of achieving SVR 
among patients receiving “Triple Therapy” treatments compared to PEG treatments (p=0.95). 




95% CI (0.30, 0.98); p=0.04)). Patients enrolled in “Other” insurance (including any non-
Commercial, non-Private Pay, non-Medicaid or non-Medicare insurance products) had a higher 
hazard of SVR compared to patients with commercial insurance (HR 1.7; 95% CI (1.08, 2.69); 
p=0.02). Other baseline clinical and demographic characteristics in the adjusted model were not 
significantly associated with SVR.  
Aim 2b Results 
Aim 2b of this dissertation modeled how treatment and cure impact risk of HRU in the HCV 
patient population- 
2b) Compare the hazard of an HRU event within 24 months of HCV diagnosis among 
patients that achieved SVR from those who did not achieve SVR, controlling for 
whether or not patients receive treatment (DAA, “Triple Therapy” or PEG).   
HRU Events among HCV+ Patients 
 Table 8 presents summary statistics of Aim 2b outcomes, including healthcare resource 
utilization (HRU, defined as any emergency, inpatient or institutional stay encounter <= 24 
months following first HCV+ date), with patients stratified by whether or not they received HCV 
antiviral treatment. The proportion of patients experiencing one or more HRU events <= 24 
months following first HCV+ date was 22% among patients who received antiviral treatment, 
compared to 46% among patients who did not receive treatment (p=0.03). The mean (SD) 
number of HRU events experienced were 2.4 (2.6) and 3.1 (2.8) among patients who did and did 
not receive treatment, respectively (p=0.08). The mean (SD) number of liver-related HRU events 






Table 8 – Healthcare Resource Utilization (HRU) Measures <= 24 months following first HCV+ 




n = 424 
No Antiviral 
Treatment  
















Mean (SD) Number of liver-disease-






1 ** and *** denotes significance at p<0.05 and p<0.01, respectively.  
 
Time to HRU following HCV+ 
 Table 9 is a summary of the Anderson-Gill intensity models of the hazard of HRU events 
<= 24 months following first HCV+ date, with time-varying covariates for treatment exposure 
drug class, as well as a time-varying covariate for achieving SVR.  The model in table 9 contains 
all patients HCV+ and controls for treatment exposure through the time-varying treatment 
exposure variable (n=1,733). “No treatment exposure” is the referent category for treatment 



















Table 9 – Adjusted Anderson-Gill Intensity Models of time to Healthcare Resource Utilization 
Events <=24 months following first HCV+ date among all patients HCV+ 
 Hazard Ratio (HR) 
(95% CI) (All 
HCV+) 
n = 1,733 
p-value Sig1 
Treatment Exposure (referent is no treatment exposure) 
Time-varying PEG2 Rx exposure 1.2 (0.99, 1.46) 0.06  
Time-varying DAA+PEG3 Rx exposure 1.11 (0.45, 2.71) 0.82  
Time-varying DAA4 Rx exposure 1.1 (0.75, 1.62) 0.62  
Treatment Response (Sustained Virologic Response (SVR); referent is No SVR) 
Time-varying SVR 0.66 (0.58, 0.75) <0.01 *** 
Demographics 
Age at First HCV+ Date 0.98 (0.98, 0.99) <0.01 *** 
Baby Boomer (born 1945-1965; referent is non-Baby 
Boomer) 
0.88 (0.77, 1.01) 0.07  
Male (referent is Female) 0.95 (0.85, 1.06) 0.37  
Year of First HCV+ 1.01 (0.97, 1.06) 0.50  
No. Years Enrolled Prior to First HCV+ Date 1.01 (0.98, 1.04) 0.40  
Race/Ethnicity (referent is White) 
African American 1.27 (1.05, 1.53) 0.01 ** 
Hispanic 1.28 (1.06, 1.54) <0.01 *** 
Other 1.23 (1.08, 1.39) <0.01 *** 
Insurance Status at First HCV+ Date (referent is Commercial Insurance) 
Medicaid 1.37 (1.07, 1.78) 0.01 ** 
Medicare 1.38 (1.17, 1.62) <0.01 *** 
Other 1.02 (0.77, 1.35) 0.89  
Baseline (<=12 Months prior to First HCV+ Date) Clinical Characteristics 
FIB-4 Score 1.04 (1.02, 1.06) <0.01 *** 
Obesity (referent is no Obesity) 1 (0.89, 1.13) 0.99  
Depression (referent is no Depression) 1.19 (1.05, 1.35) <0.01 *** 
Baseline Total Quan Score 1.13 (1.1, 1.16) <0.01 *** 
1 ** and *** denotes significance at p<0.05 and p<0.01, respectively. 
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 Several covariates were significantly associated with the rate of recurrent HRU events. 
Achieving SVR was significantly associated with a reduced hazard of HRU (HR 0.66; 95% CI 
(0.58, 0.75); p<0.01). Increased age at HCV+ was associated with a reduced hazard of HRU (HR 
0.98, 95% CI (0.98, 0.99); p<0.01). Compared to Whites, patients of African American, Hispanic 
or other racial and ethnic backgrounds all had a significantly (p<0.01) higher hazard of HRU. 
Compared to commercially insured patients, patients with Medicaid or Medicare insurance 
coverage had a significantly (p<0.01) higher hazard of HRU. Higher baseline liver fibrosis (Fib-
4 Score) was associated with increased hazard of HRU (HR 1.04, 95% CI (1.02, 1.06); p<0.01). 
Baseline depression and total Quan comorbidity scores were all significantly (p<0.01) associated 
with an increased hazard of HRU. 
 Table 10 is a summary of the Anderson-Gill intensity model of the risk of recurrent HRU 
events <= 24 months following first HCV+ date, with time-varying covariates for treatment 
exposure drug class, as well as a time-varying covariate for achieving SVR, among only patients 
who receive treatment (n=424). “PEG” is the referent category for time-varying treatment 
exposure. 
 The model in table 10 in shows that SVR continued to have a significant impact on 
reducing HRU (HR 0.72, 95% CI (0.51, 0.99); p=0.04).  Compared to PEG treatment, DAA and 
“Triple Therapy” treatment was not significantly associated with HRU. Compared to Whites, 
African Americans were significantly more likely to experience HRU (HR 1.72; 95% CI (1.11, 
2.66); p=0.02). Baseline liver fibrosis (Fib-4 Score) was significantly associated with a higher 
hazard of HRU (HR 1.08, 95% CI [1.04, 1.12]; p<0.01). Baseline depression (HR 1.19, 95% CI 
(1.05, 1.35); p<0.02), as well as total Quan comorbidity scores (HR 1.13, 95% CI (1.1, 1.16); 




Table 10– Adjusted Anderson-Gill Intensity Models of time to Healthcare Resource Utilization 
Events <=24 months following first HCV+ date among patients diagnosed HCV+ and receiving 
antiviral treatment 
 
HR (95% CI) (HCV+ 
and received Rx) 
n = 424 p-value Sig1 
Treatment Exposure 
Time-varying PEG2 Rx exposure Referent 
Time-varying DAA+PEG3 Rx exposure 0.93 (0.35, 2.48) 0.89 
Time-varying DAA4 Rx exposure 1.28 (0.8, 2.05) 0.31 
Treatment Response (Sustained Virologic Response (SVR); referent is No SVR) 
Time-varying SVR 0.72 (0.51, 0.99) 0.04 ** 
Demographics 
Age at First HCV+ Date 0.99 (0.98, 1.01) 0.38 
Baby Boomer (born 1945-1965; referent is non-Baby 
Boomer) 
0.83 (0.59, 1.17) 0.29 
Male (referent is Female) 0.84 (0.65, 1.09) 0.18 
Year of First HCV+ 0.96 (0.87, 1.07) 0.47 
No. Years Enrolled Prior to First HCV+ Date 1.02 (0.96, 1.08) 0.59 
Race/Ethnicity (referent is White) 
African American 1.72 (1.11, 2.66) 0.02 ** 
Hispanic 1.23 (0.82, 1.85) 0.32 
Other 0.98 (0.72, 1.34) 0.92 
Insurance Status at First HCV+ Date (referent is Commercial Insurance) 
Medicaid 0.49 (0.13, 1.35) 0.14 
Medicare 1.21 (0.79, 1.85) 0.39 
Other 0.96 (0.54, 1.69) 0.89 
Baseline (<=12 Months prior to First HCV+ Date) Clinical Characteristics 
FIB-4 Score 1.08 (1.04, 1.12) <0.01 *** 
Obesity (referent is no Obesity) 1.11 (0.85, 1.45) 0.44 
Depression (referent is no Depression) 1.48 (1.08, 2.03) 0.02 ** 
Baseline Total Quan Score 1.11 (1.02, 1.21) 0.02 ** 
1 ** and *** denotes significance at p<0.05 and p<0.01, respectively.  
 
Aim 3 Results 
 Aim 3 projects the difference in HCV disease progression outcomes (e.g. the change in 




mortality) for a hypothetical cohort of HCV+ patients, over five, 10 and 30-year time-horizons 
across four payer-based treatment strategies: 
5. Strategy 1: Advanced fibrosis, where patients receive DAA treatment if screened for F3-
F4 liver fibrosis (based on calculated Fib-4;39 current standard of care (SOC)); 
6. Strategy 2: “Moderate” fibrosis, where patients receive DAA treatment if screened for 
F2-F4 fibrosis;  
7. Strategy 3: “Minimal” fibrosis, where patients receive DAA treatment if screened for F1-
F4 fibrosis; and 
8. Strategy 4: Universal treatment, where all patients HCV+ receive DAA treatment, 
regardless of degree of liver fibrosis. 
Deterministic Results of Reductions in HCV Disease Progression under Different Treatment 
Strategies 
 Deterministic results of the Markov model are presented in table 11.  Each treatment 
strategy had an increase in total life years and QALYs compared to the SOC. Total life years and 
QALYs for the F0-F4 strategy were higher after five years (4.41 and 3.50), 10 years (7.95 and 
6.56) and 30 years (14.95 and 12.58) than F2-F4 and F1-F4 treatment strategies. Cumulative 
incidence of HCV disease progression outcomes (DC, HCC and LT) was lower in each treatment 
strategy compared to the SOC, although cumulative incidence in the F2-F4, F1-F4 and F0-F4 






Table 11 – Deterministic Results of HCV Disease Progression Simulations of Treatment 
Strategies1 
Standard of Care (SOC) Treatment Strategy–  
Cumulative Incidence of Disease Outcomes 
















5yrs 4.37 2.58 1.45% 2.22% 0.01% 
10yrs 7.80 4.71 1.95% 2.63% 0.07% 
30yrs 14.11 9.39 3.96% 3.73% 0.62% 
F2-F4 Treatment Strategy   
LY2 QALYs2 DC HCC LT 
5yrs 4.38 3.24 1.44% 2.21% 0.01% 
10yrs 7.85 6.05 1.93% 2.59% 0.07% 
30yrs 14.49 11.62 3.80% 3.58% 0.60% 
F1-F4 Treatment Strategy  
 
LY2 QALYs2 DC HCC LT 
5yrs 4.40 3.44 1.44% 2.21% 0.01% 
10yrs 7.92 6.43 1.93% 2.59% 0.07% 
30yrs 14.82 12.26 3.80% 3.58% 0.60% 




LY2 QALYs2 DC HCC LT 
5yrs 4.41 3.50 1.44% 2.21% 0.01% 
10yrs 7.95 6.56 1.93% 2.59% 0.07% 
30yrs 14.95 12.58 3.80% 3.58% 0.60% 




 Incremental effectiveness results of each strategy against the SOC are presented in table 12. 
Incremental effectiveness was calculated as the difference in effectiveness measure between each 
strategy and the SOC (e.g. QALYsF0-F4 – QALYsSOC). Each strategy was more effective over the 
SOC, particularly in incremental gains in life years and QALYs. The F0-F4 strategy was the 
most effective in increasing life years and QALYs compared to the SOC, with gains of 0.84 life 
years (3.19 QALYs) over 30 years compared to the SOC. Each treatment strategy did have an 




compared to the SOC, though again the F2-F4, F1-F4 and F0-F4 strategies were roughly 
equivalent in incremental effectiveness. 
 
Table 12 – Incremental Effectiveness (IE) of Different Treatment Strategies* Compared to 
Standard of Care (SOC)1 
















5yrs 0.01 0.65 0.00% -0.01% 0.00% 
10yrs 0.05 1.34 -0.03% -0.04% 0.00% 
30yrs 0.38 2.22 -0.16% -0.15% -0.02% 
F1-F4 Treatment Strategy 
Time 
Interval 
LY2 QALYs2 DC HCC LT 
5yrs 0.02 0.86 0.00% -0.01% 0.00% 
10yrs 0.12 1.72 -0.03% -0.04% 0.00% 
30yrs 0.71 2.87 -0.16% -0.15% -0.02% 
F0-F4 “Universal” Treatment Strategy 
Time 
Interval 
LY2 QALYs2 DC HCC LT 
5yrs 0.03 0.92 0.00% -0.01% 0.00% 
10yrs 0.15 1.85 -0.03% -0.04% 0.00% 
30yrs 0.84 3.19 -0.16% -0.15% -0.02% 
1Treatment strategies based on degree of liver fibrosis, defined by Metavir score (source: Cox-North et al 2018).166 
2 Discounted. 
 
 Figure 8 graphs the cumulative life years (discounted) of each strategy over a 30-year time 
horizon. The difference in cumulative life years across strategies is most evident after 15 years, 
with the F0-F4 strategy having the highest cumulative life years compared to the other strategies. 
Cumulative life years begin to converge again after 15 years, though even after 30 years the F0-






Figure 8 – Cumulative Life Years over 30 years across Treatment Stategies1 
1Treatment strategies based on degree of liver fibrosis, defined by Metavir score(source: Cox-North et al. 2018).166 
 
 Figure 9 graphs the cumulative QALYs (discounted) of each strategy over a 30-year time 
horizon. The difference in cumulative life years across strategies is most evident within the first 
10 years, with each strategy treatment strategy having considerably higher cumulative QALYs 
than the SOC. F2-F4, F1-F4 and F0-F4 strategies result in an initial net increase in cumulative 
QALYs within the first four years. Cumulative QALYs begin to converge again after 10 years, 
though even after 30 years the F0-F4 strategy has the highest cumulative QALYs. 
 Figures 10-12 graph the cumulative incidence of HCV disease progression outcomes (DC, 
HCC and LT) over a 30-year time horizon. The F2-F4, F1-F4 and F0-F4 strategies are all 
effective in reducing the cumulative incidence of HCV disease progression outcomes over the 
SOC, though differences in disease progression between F2-F4, F1-F4 and F0-F4 are 
indistinguishable. Lower cumulative incidence is evident after 14 years, 10 years and 25 years 
























Cumulative Life Years (discounted) over 30 years Across Treatment 
Strategies1
Standard of Care F2-F4 Treatment Strategy





Figure 9 – Cumulative Quality Adjusted Life Years (QALYs) over 30 years across Treatment 
Stategies1 
1Treatment strategies based on degree of liver fibrosis, defined by Metavir score (source: Cox-North et al. 2018).166 
 
 
Figure 10 – Cumulative Incidence of Decompensated Cirrhosis  over 30 years across Treatment 
Stategies1 























Cumulative QALYs (discounted) over 30 years Across Treatment 
Strategies1
Standard of Care F2-F4 Treatment Strategy























Cumulative Incidence of Decompensated Cirrhosis over 30 years Across 
Treatment Strategies1
Life Years Standard of Care F2-F4 Treatment Strategy





Figure 11 – Cumulative Incidence of Hepatocellular Carcinoma over 30 years across Treatment 
Stategies1 
1Treatment strategies based on degree of liver fibrosis, defined by Metavir score (source: Cox-North et al. 2018).166 
 
 
Figure 12 – Cumulative Incidence of Liver Transplants over 30 years across Treatment 
Stategies1 
























Cumulative Incidence of Hepatocelluar Carcinoma over 30 years Across 
Treatment Strategies1
Standard of Care F2-F4 Treatment Strategy





















Cumulative Incidence of Liver Transplants over 30 years Across 
Treatment Strategies1 
Standard of Care F2-F4 Treatment Strategy




Probabilistic Sensitivity Analysis 
 To quantify the overall uncertainty in the model inputs and the impact on model 
outputs, I performed a probabilistic sensitivity analysis (PSA). The results of the PSA are 
described in figure 15. The proportion of simulations resulting in an increase in QALYs was 
compared between each treatment strategy. The F2-F4, F1-F4 and F0-F4 strategies generated 
increases in QALYs over the SOC in 100% of the simulations. Compared to the F2-F4 strategy, 
the F1-F4 strategy generated increases in QALYs in 100%, 99.7% and 98.6% of simulations 
over five-year, 10-year and 30-year time horizons, respectively. The F0-F4 strategy produced 
increases in QALYs over the F2-F4 strategy in 100% of simulations. The F0-F4 strategy 
generated increases in QALYs compared to the F1-F4 strategy in 98.5%, 98.9% and 99.9% of 










Aim 1 Discussion 
Aim 1 of this dissertation describes the HCV+ patient population in a large, integrated 
health system (Kaiser Permanente Colorado (KPCO)) from January 1, 2005-December 31, 2015; 
as well as the clinical and demographic characteristics that contribute to the likelihood of these 
patients receiving HCV antiviral therapy within 24 months of diagnosis. 
Figure 6 shows the proportion of adults HCV+ (approximately 0.3%) is similar to 
published prevalence estimates of HCV prevalence among commercially insured adults in the 
U.S (approximately 0.2%; Johnson et al. (2015)).170 The small difference can be explained by 
data sources (EHR v. national claims database; HCV RNA lab results v. ICD-9 diagnosis codes), 
as well as sampling (this dissertation included all adults >=18 years of age, Johnson et al. 
included only adults 18-64 years of age).  
Among HCV patients enrolled at KPCO, only 52% were continuously enrolled at least 12 
months prior to their first HCV RNA+ lab result. These results highlight that nearly half of 
patients diagnosed with HCV at KPCO 2005-2015 were new to the health system. Prior research 
has shown HCV patients have higher healthcare resource use and cost than the overall patient 
population.171 
The Importance of Treatment Eras 
Chapter 4, Table 2 highlights the importance of describing the HCV+ patient population 
by Era of diagnosis. The proportion of patients HCV+ who received treatment during Era 3 
(January 1, 2014-December 31, 2015; when PEG-free DAAs are available) is higher (both at any 
point following diagnosis and <= 24 months following diagnosis) than the proportion of patients 




shorter for patients in Era 3 compared to Eras 1 and 2. More patients received treatment sooner 
than in prior years. Other studies have emphasized how increased prescribing of antiviral 
treatment can reduce HCV disease burden and liver-related adverse outcomes49,58,167. 
Nevertheless, less than 50% of HCV+ patients in any Era, including Era 3, received treatment, 
highlighting the gaps in the care continuum remain. 
Chapter 4, Table 2 demonstrates the similarities and differences among patients who do 
and do not receive treatment within each Era. While patients receiving treatment in Eras 1 and 2 
were younger than patients who did not receive treatment, patients in Era 3 are older than 
patients who did not receive treatment. Patients receiving treatment had a lower average baseline 
Quan comorbidity score than patients who did not receive treatment within each Era. 
Comorbidities, including chronic infections such as HIV, advanced liver disease (decompensated 
cirrhosis), and other chronic conditions with potential adverse medication interactions with HCV 
antivirals, may influence whether or not patients receive treatment.12,60,68 
Factors Associated with Receiving Antiviral Treatment 
Logistic regression results show that the probability of receiving treatment in Era 3 is 
most influenced by race and socioeconomic factors. In Era 3, the odds of African Americans 
receiving treatment were 76% lower than Whites. Patients covered by Medicaid insurance in Era 
3 had 64% lower odds of receiving treatment than patients with commercial insurance. 
Compared to other races, African American HCV+ patients have historically had lower rates of 
SVR with PEG therapies, however randomized clinical trials of DAA therapies report similar 
SVR rates across patients of different racial backgrounds.53 Race and insurance coverage patient 
characteristics may be acting as a proxy for patients’ socioeconomic factors, particularly cost-
related barriers to care.172,173 Indeed, several studies have highlighted the cost of DAA treatment 




The association between obesity and receiving treatment (obese patients are three times 
more likely to receive treatment than non-obese patients) among patients in Era 3 may be derived 
from several factors.  Prior research has shown that the majority of referrals to gastroenterology 
(GI) in recent years have been due to HCV.175 Obesity is associated with fatty liver disease and 
ascites, which in turn is associated with both liver fibrosis and increased abdominal girth. 
Obesity is also a significant predictor of treatment failure.176 Obese patients may present with 
more liver disease risk factors and be more likely to be referred to GI for additional liver 
screening, and, if HCV+, for antiviral treatment. 
Among patients in Eras 1 and 2, there were few significant (p<0.05) covariates related to 
the likelihood of receiving treatment (age at HCV+ date for patients in Era 2; Medicare insurance 
coverage and Quan comorbidity score for patients in Era 1). These results may highlight several 
clinical considerations during earlier eras of treatment. First, HCV testing guidelines for 
universal screening of “Baby-Boomer” birth cohort patients were not implemented until 2012,177 
thus only patients with HCV risk factors were likely to be tested for the disease. Second, due to 
tolerability concerns for older treatments, patients with comorbid conditions or other risk factors, 
may have been less likely to be prescribed antiviral treatment.178  Finally, providers who were 
aware of newer, more efficacious DAA treatments coming to market may have postponed 
prescribing PEG or “triple therapy” treatments to older patients until DAAs were available.155,178-
180 
Aim 1 Strengths 
 Aim 1 of this dissertation uses EHR data to capture clinical data on the HCV population 
in a managed care setting. Specifically, Aim 1 uses HCV RNA+ laboratory results to define the 
HCV+ patient population, rather than relying simply on ICD-9 or ICD-10 diagnosis codes. The 




accurate estimate of the HCV-infected population in KPCO. A diagnosis in the absence of the 
lab result could be assigned to a patient due to clinical or demographic characteristics that may 
suggest HCV infection, or for billing HCV screening and subsequent treatment in claims data 
systems.  
 Further, the use of EHR data linked with claims data provides additional clinical data not 
available in claims or EHR data sources alone, including lab results for calculating the FIB-4 
(degree of liver fibrosis calculated from an algorithm including ALT, AST and Platelet lab 
results);39 BMI, calculated from objectively-measured heights and weights; and pharmacy 
dispensing data to capture what patients actually received in the pharmacy.  
 Aim 1 focuses on a managed care patient population in the U.S., a population often 
understudied in HCV research. This research highlights the gaps in receiving treatment, even 
among patient populations not considered vulnerable or underserved. Further, the patient 
population of KPCO captures a diverse mix of commercially insured, Medicare and Medicaid 
patient populations within one system. 
Aim 1 Limitations 
 There are several limitations to Aim 1. Aim 1 assumes HCV+ at the first date available 
within each patient’s EHR. HCV is a chronic condition, and patients diagnosed in one year may 
have actually become infected years (or even decades) prior. Similarly, patients may have 
received testing and/or HCV treatment at a provider outside of KPCO years prior, with no record 
of such treatment in their current EHR. Testing, diagnosis and treatment data is limited to the 
availability of the EHR data of KPCO, as well as the patient’s enrollment in the health system. 
By identifying a 12-month washout period for no prior HCV RNA+ labs or HCV antiviral 
treatment, I have created an “incident” cohort of HCV+ patients for this dissertation; in reality a 




 Aim 1 utilized EHR data to establish patients’ clinical and demographic characteristics. 
These data did not, however, capture important socioeconomic data, such as insurance product 
details (e.g. specific prescription drug coverage plan options, copays, deductibles and out-of-
pocket maximums), which may elucidate how costs of care may influence receiving treatment.173 
Similarly, patient-specific socioeconomic status (SES) variables (e.g. patient household income) 
were unavailable, limiting the ability to specifically identify socioeconomic status of patients 
which likely contributes to their ability to receive treatment through their healthcare payer 
source, or pay for treatment (including copays for commercially insured patients). Medicaid 
insurance coverage was used as a broad proxy for SES, as Medicaid coverage has specific 
income and other SES requirements (e.g. total household income at-or-below a percentage of the 
Federal Poverty Limit).123,124 
 HCV screening rates are increasing in the U.S.,157 but increases in testing and treating 
patients diagnosed with HCV are not fully captured in Aim 1. The study design of Aim 1 was 
limited to only patients whose first HCV+ diagnosis could be identified between January 1, 
2005-December 31, 2015; receipt of treatment is identified <= 24 months following diagnosis 
(through 12/31/2017). Since 2015, HCV screening guidelines include universal screening of all 
baby boomers (in addition to patients with risk factors); newer, more affordable treatments and 
greater patient advocacy have increased the number of patients screened for HCV and the 
number of patients receiving treatment. Further analyses should be conducted with patients 
HCV+ after 2015 to better understand the more recent developments in HCV care management. 
 The use of first treatment dispensing as the outcome for the Aim 1 model limits does not 
account for whether patients completed treatment, an important factor for whether or not they 




data should be conducted to not only to quantify the likelihood of receiving treatment, but also 
the likelihood of completing a treatment regimen and the likelihood of achieving SVR. 
Aim 1 Conclusion 
 Aim 1 identified specific patient characteristics that were and were not associated with 
receiving HCV antiviral treatment. Within Eras 1 and 3, comorbid conditions were significant 
factors contributing against receiving treatment. Within Era 2, only patient age had a significant 
association with receiving treatment. Certain race and ethnicity categories and insurance status 
were significantly associated with not receiving treatment among patients in Era 3, suggesting 
SES factors and costs of treatment are the biggest barriers to receiving care. Patients who do not 
receive treatment will not achieve SVR, increasing their likelihood for HCV disease progression. 
Health systems should work to reduce barriers to treatment, including more robust screening 
efforts, reduction or elimination of prior authorization requirements, and lower patient out-of-
pocket costs so that more patients can afford DAAs and reduce HCV disease burden. 
Aim 2a Discussion 
 Aim 2a of this dissertation estimates the time-to-SVR within 24 months of diagnosis 
among patients in the HCV population who received treatment. The analyses included estimating 
the proportion of patients who received treatment following their first HCV RNA+ lab result, 
estimating the proportion of patients who received treatment and achieved SVR, and, among 
patients who received treatment, estimating the time-to-SVR across different treatment regimens 
(PEG, “Triple Therapy” and DAA).  
Achieving SVR 
 The 24-month follow-up window for treatment exposures reflect the current treatment 
regimens available at the date of HCV+ (i.e. all patients HCV+ 2005-2010 received PEG 




HCV+ 2014-2015 received DAA regimens). Thus SVR rates calculated for each treatment 
regimen reflect the SVR hazard of the treatment regimens available during the time of HCV 
diagnosis.  
Chapter 4, Table 5 shows an SVR rate of 53%, 71% and 77% among patients receiving 
PEG, “Triple Therapy” and DAA treatments, respectively. The SVR rates for patients receiving 
PEG and “Triple Therapy” are similar to the SVR rates reported in clinical trials for these 
respective treatment regimens, albeit closer to the upper limit (see Chapter 2, table 1). The SVR 
rate for patients receiving DAA treatment regimens is lower than reported in clinical trials (see 
Chapter 2, table 1), but closer to results identified in real-world, retrospective cohort studies of 
DAA SVR rates.34,149,181  
Chapter 4 Tables 6 and 7 describe the unadjusted and adjusted likelihood of achieving 
SVR by treatment exposure type. In both the unadjusted and adjusted models, patients receiving 
DAA achieved SVR at over twice the rate of patients who receive PEG, as reflected in the hazard 
ratios. The rate of SVR for patients receiving “Triple Therapy” was not significantly different 
from the rate for patients receiving PEG.  
African Americans achieved SVR at nearly half the hazard of Whites (46%) across 
treatment exposure groups. As in Aim 1 analyses, race may be acting as a proxy for more 
specific SES indicators.173 The adjusted model uses only patients who received treatment, but 
treatment regimens often require considerable patient follow-up visits and ongoing labs to 
monitor progress and arrange interventions should adverse events occur.34 Patients of low SES 
(or alternatively, patients with insurance plans that have high deductibles and other out-of-pocket 
costs that may make affording care difficult) may not complete treatment or otherwise fail to 




Insignificant baseline clinical and demographic characteristics in the adjusted model 
suggest patients with similar clinical and demographic characteristics respond similarly to 
treatment. The tolerability of PEG and “Triple Therapy” regimens (including ribavirin, which 
also had tolerability issues for many patients), as well as adverse side-effects related to 
peginterferon use, has made providers appropriately selective of patients who were referred for 
these antiviral treatments.175,180 With fewer tolerability and adverse events associated with DAA 
treatment, cost likely drives decision making among patients with DAA treatment exposure, and 
whether any underlying comorbid conditions may adversely impact treatment completion and 
subsequent cure. 
Aim 2a Strengths 
Aim 2a of this dissertation is one of the first studies to use time-to-event analysis to 
calculate real-world hazard of SVR among a managed care patient population in Colorado. This 
dissertation goes beyond the calculation of an SVR rate for patients exposed to specific antiviral 
treatments and estimates the time between diagnosis and cure for patients receiving treatment.   
Aim 2a provides a head-to-head comparison of patients receiving all three classes of 
antiviral treatment regimens available since 2005, providing a comprehensive view of how the 
likelihood of treatment compares across available regimens. The comparison of older to newer 
treatments is important because, while DAAs have become the standard of care in the majority of 
clinical settings, many vulnerable patient populations (some incarcerated populations, poorer 
communities where DAAs are unaffordable) still receive PEG treatment; thus it is important to 
continue to highlight the strengths of DAAs over “triple therapies” and PEG.  
Aim 2a Limitations 
 There are several limitations to Aim 2a. Lower proportions of patients achieving SVR 




for this dissertation. Limited follow-up time is a significant factor in accurately measuring a 
DAA-specific SVR, and a rate of SVR attainment among patients receiving DAA treatment. 
Patients HCV+ 2014-2015 were followed for 24 months (through 12/31/2017) for any treatment 
exposure and subsequent SVR. Given DAA treatment duration typically lasts 8-12 weeks, SVR 
is not measured until at least 12 weeks (three months) following completion of a treatment 
regimen, and the average number of days between HCV+ diagnosis and first treatment exposure 
was 282.5 (chapter 4, table 5), some patients may simply not had enough follow-up time 
available to have completed treatment, let alone achieve SVR. Thus the lower SVR rate for DAA 
treatment regimens may not reflect treatment efficacy so much as data availability. Additional 
follow-up data would likely produce a higher SVR rate among patients with DAA exposure. 
 The unadjusted and adjusted models in Aim 2a account for time-varying treatment 
exposures, but it does not explicitly measure treatment completion. PEG and “Triple Therapy” 
regimens had considerable adverse side effects and treatment tolerability issues, limiting 
treatment completion rates and thus reducing SVR attainment rates. This creates considerable 
programmatic complexity in determining exactly when a given polypharmacy regimens ends. 
SVR attainment was chosen as an outcome to mitigate this complexity, as it is easier to identify a 
specific lab result within a date range following the last prescription drug dispensing of a 
regimen (plus days supplied) than to distinguish specific treatment dispensing dates, days 
supplied, and gaps that constitute discontinuation.   
 Lacking SES variables for individual patients may not fully capture their interaction with 
the health system. Race/ethnicity and insurance status can act as proxies for SES status,172 but 
income levels, as well as insurance product specifics (including deductibles, copays and any 





Aim 2a Conclusions 
 SVR is attained in shorter time and at higher rates for patients receiving DAA treatment 
compared to patients receiving PEG treatment. Racial disparities in achieving SVR exist across 
antiviral treatment regimens. Highlighting the efficacy of DAA treatment using time-to-event 
analysis provides a novel approach to understanding SVR rates through hazard ratio estimates. 
Achieving SVR at faster and higher rates is important as the HCV patient population, 
particularly the Baby-Boomer birth cohort, continues to age, as it can limit or reduce further 
HCV disease progression and future disease-related adverse outcomes, as well as subsequent 
health care resource utilization (HRU). The impact of SVR attainment on HRU is assessed in 
Aim 2b.  
Aim 2b Discussion 
 Aim 2b measures the impact of HCV antiviral treatment, as well as subsequent cure 
(SVR) on HRU events (inpatient and emergency department visits) following HCV diagnosis. 
Aim 2b compared the proportion of patients who had an HRU event within 24 months following 
HCV+ date; the average number of HRU events and the hazard of HRU events among patients 
who do and do not receive treatment, as well as among patients who receive treatment and do 
and do not achieve SVR. 
 Results in Chapter 4, Table 8 show that a significantly lower proportion of patients who 
receive treatment have an HRU event within 24 months of diagnosis compared to patients who 
do not receive treatment. Patients receiving treatment had fewer HRU events, on average, than 
patients who do not. There was no statistically significant difference in the number of liver-
related HRU events between patients who do and do not receive treatment.  
HCV+ patients who achieved SVR after treatment experienced significantly lower hazard 




long-term liver-related adverse outcomes.66,157 The analyses conducted in Aim 2b provide 
estimates relevant to health systems concerned about near-term, costly adverse events (HRU).  
Among patients who did and did not receive treatment, non-White patients had higher 
hazard of HRU. These results may be confounded with broader patient characteristics and not 
specifically related to HCV. Research has shown racial and ethnic minorities may not utilize 
preventative care to the same extent as Whites, due to real (cost, access) and perceived 
disparities in care.172 Similarly, minority patients in this dissertation may be less willing to utilize 
preventative services, waiting instead until their condition worsens and requiring an emergency 
or inpatient visit.  
However, African Americans have higher hazards of HRU among all HCV patients and 
even among patients who received HCV treatment. This result has carried forward from prior 
Aims in this dissertation; African Americans were also significantly less likely to receive 
treatment compared to Whites (Aim 1); and thus less likely to achieve SVR (Aim 2a) and more 
likely to experience HRU (Aim 2b). Race remains a significant factor in measuring the risk of 
HRU, even after controlling for baseline comorbid conditions. Again, this may be due primarily 
to broader cost and access issues and inherent racial and ethnic disparities.172  
HRU encounters are expensive for both the patient and the health system. One study of 
Medicare claims found per-person IP, diagnosis-related group (DRG)-based total costs can range 
approximately $16,000-$20,000. 182 Other studies have shown per-person ED visits to cost 
approximately $25,000.183 An HCV patient with multiple HRU events can quickly exceed the 
costs of DAA treatment. Health systems should note the cost savings of reduced HRU as further 
rationale to reduce patient’s costs for CHV treatment expand DAA prescribing. 
Reducing HRU through treatment limits the cost and utilization burden of the health 




infection are generally larger uses of healthcare services (including outpatient, ED and IP visits), 
and HRU is highest among “Baby Boomer” birth cohort patients.171 Other research has shown 
ED visits make up a larger proportion of the total costs of care for HCV patients receiving 
“Triple Therapy” compared to DAA treatment.34 The results of this dissertation show patients 
who received DAA have improved outcomes through lower rates of HRU. 
Aim 2b Strengths 
 Aim 2b measures HRU events following diagnosis among an HCV+ patient population in 
a managed care setting. Other studies have quantified overall HRU for HCV+ patients;170,171 this 
dissertation is the first to measure HRU using time-to-event analysis. HRU events are costly for 
health systems and often for patients themselves. Quantifying the risk of HRU among all HCV+ 
patients and controlling for baseline comorbid conditions (Quan Comorbidity Index), treatment 
exposure and subsequent cure (SVR), provides a quantifiable measure of how HCV impacts 
utilization and how treatment of HCV infection can limit HRU. Further, HRU as a measure of 
disease burden provides a more tangible measure for health systems to quantify HCV disease 
burden, as HCV disease outcomes (cirrhosis, liver failure, hepatocellular carcinoma, liver 
transplants, etc.) may take years to develop among HCV+ patients. HRU is an outcome that 
health systems want to reduce. 
 The use of the Anderson-Gill intensity model to capture repeated measures of HRU 
(rather than simply the first HRU event in traditional time-to-event models) allows the model to 
account for subsequent HRU events (e.g. an ED visit that leads to an IP stay will capture 
additional risk that the ED visit alone would not). Further, the lack of memory in the Anderson-
Gill model provides a more conservative estimate of HRU, as prior HRU does not increase the 




Aim 2b Limitations 
There are several limitations to Aim 2b. Patient-level SES covariates could provide a 
more comprehensive measure of health care affordability which may better elucidate how 
patients interact with the health system, as well as their likelihood for receiving HCV treatment. 
As with Aim 2a, additional follow-up time for treatment completion and SVR achievement 
would likely provide more robust estimates of the impact of treatment and cure on HRU. 
Additionally, more follow-up time could provide more HRU events to incorporate into the 
analyses.  
HRU was chosen as an outcome for Aim 2b to capture a near-term outcome measure 
important to both patients and health systems. Many HCV outcomes studies (and Aim 3 of this 
dissertation) forecast reductions in disease-specific outcomes.4,167,180 There was not sufficient 
follow-up in this dissertation to quantify specific HCV outcomes of interest (e.g. cirrhosis, 
hepatocellular carcinoma and liver transplant), which may not present in patients until five or 
more years following diagnosis. Thus HRU was chosen as an alternative outcome measure.  
HRU was defined as any emergency or inpatient stay <= 24 months following HCV+ 
diagnosis. Additionally, there was not sufficient sample size to model emergency department and 
inpatient hospital encounters separately. The ability to provide more granular estimates of 
specific types of HRU would provide health systems with a clearer picture of how 
treatment/SVR impacts specific lines of business. 
The Anderson-Gill Intensity model allows for repeated events as an outcome, however 
the model does not allow for “memory”, where patients who had an event in the prior period 
have a higher likelihood of another event. The model provides more conservative estimates of 
likelihood of HRU, although using different repeated events proportional hazards model may 




Aim 2b Conclusions 
Aim 2b highlights that achieving SVR has a quantifiable impact on near-term and costly 
HRU outcomes. If more patients diagnosed with HCV can receive DAA treatment, they are more 
likely to achieve SVR, which significantly reduces their risk of HRU events. Health systems 
should consider providing affordable HCV treatment to HCV patient populations as it not only 
improves patient outcomes but reduces costly HRU they must support. 
Aim 3 Discussion 
 Aim 3 of this dissertation projects the effectiveness of DAA treatment strategies on 
patient quality of life measures and HCV disease progression from a health system perspective. 
Using a Markov simulation model and a hypothetical cohort of HCV+ patients, I project 
increases in life years (LY), quality-adjusted life years (QALYs) and cumulative incidence of 
disease outcomes (decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and liver 
transplant (LT)) from strategies that progressively reduce the time between HCV diagnosis and 
receipt of DAA treatment.  
Comparable Studies to Aim 3 
 Other studies have explored the timing of treatment and how it impacts disease 
progression at patient population- and health system-levels. Chhatwal et al. (2015) explore the 
cost effectiveness analyses (CEA) of ledipasvir and sofosbuvir to interferon-based treatments in 
a CEA and budget impact analysis with a third-party payer perspective over 10-, 20- and 30-year 
time horizons.32 The authors found that, compared to interferon treatment, ledipasvir/sofosbuvir 
generated an incremental QALY per person of 0.56, which varied considerably by patient’s prior 
treatment history, genotype and degree of liver fibrosis. Ledipasvir/sofosbuvir is found to be 
cost-effective between 82% and 60% of the time among treatment-naïve and treatment-




 Chidi et al. (2016) perform a similar analysis to this dissertation, using a Markov 
simulation to compare the cost-effectiveness of different treatment strategies for 45-55 year old 
Medicaid beneficiaries from Medicare alone and Centers for Medicare and Medicaid Services 
(CMS) perspectives.29 The authors found that, compared to the standard of care (treatment of 
HCV+ patients with advanced liver fibrosis),  the full access (universal treatment) strategy 
provided incremental QALY gains of 0.82-3.01. The full access strategy generated cost savings 
in 93$ of model iterations in PSA.  
 Rattay et al (2017) studied the impact of HCV screening and treatment for HCV+ patients 
who were and were not enrolled in the primary care patient panel from the Extension for 
Community Healthcare Outcomes (Project ECHO) in New Mexico.40 The model utilized many 
inputs calculated from patients in project ECHO, including screening rates, SVR and other 
transition probabilities. The authors used sofosbuvir and velpatasvir as their primary treatment 
exposure. The authors found that HCV infected patients enrolled in Project ECHO who received 
treatment gained lifetime incremental QALYs of 3.07 over patients with HCV not enrolled in 
Project ECHO (0.015 QALYs per person in a Project ECHO patient panel; 35 QALYs for a 
given physician’s patient panel and 770 QALYs for an ECHO hub with 22 spokes).40 
Early Treatment Improves Outcomes 
 Every successive strategy compared to the standard of care (SOC) improves patient 
outcomes over time. Early DAA treatment slows or reverses HCV disease progression.3,4 LYs 
and QALYs had the largest improvements in outcomes as across strategies, with the “Universal” 
treatment strategy (patients receive DAA treatment as soon as they are diagnosed) providing the 
largest improvements. Patients experience gains in Lys and QALYs within five years of 
receiving treatment, which in turn reduces HCV disease burden and healthcare utilization for 




Implications for Health Systems and Payers 
Increases in QALYs over the SOC are most evident within the first five years of 
diagnosis/treatment (see chapter 4, figures 9 and 14), and remain above the SOC even after 30 
years.  Differences in disease progression among strategies were negligible, but all strategies 
reduced DC, HCC and LT over the SOC. Reductions in DC and HCC become most apparent 
after 15 years (chapter 4, figures 10 and 11); reductions in LT are more evident after 25 years 
(chapter 4, figure 12).  
 Probabilistic sensitivity analysis (PSA) results show that the Universal treatment strategy 
is the dominant strategy for improving QALYs (see chapter4, figure 15). These results are 
similar to results in other simulation analyses of HCV disease progression.155,157,167 By slowing 
or preventing disease progression, patients experience fewer adverse outcomes and greater 
quality of life over time.  
Taken together, Aim 3 of this dissertation highlights measurable benefits to patients (and 
by extension, health systems) within five years of receiving treatment. Health systems and payers 
should consider these more near-term gains in LYs and QALYs for their patients when deciding 
when to provide treatment.  
Aim 3 Limitations 
 There are several limitations to Aim 3. DC, HCC and LT outcomes may not present in 
HCV for years (even decades) following infection. The novelty of DAA treatment means there 
isn’t sufficient real world data to highlight differences in these disease progression outcomes. 
Disease progression estimates are derived from DAA SVR rates and disease progression 
estimates from HCV populations prior to the availability of DAAs (PEG and “Triple Therapy” 
treatment regimens). Indeed, the efficacy of DAA treatments may be so strong that this 




 While population estimates were taken from Aims 1 and 2 of this dissertation where 
available, including age distributions and calculated SVR rates, input parameters for the Markov 
model were derived largely from literature estimates. In most cases estimates came from other 
commercially-insured HCV patient populations in the U.S., but some estimates were derived 
from other patient populations, including Veterans Affairs and populations residing in other 
countries. 
 The use of Fib-4 scoring to approximate liver fibrosis and disease severity are based on 
other models of HCV disease progression at a population level, but unlike a liver biopsy it is not 
the gold standard for clinical disease progression. The levels chosen for each strategy reflect how 
payers have allocated resources to their respective HCV+ patient populations, which is the 
perspective of this model. A more accurate measure would be to estimate disease progression 
from large samples of patients who received liver biopsies to effectively pinpoint disease 
progression. 
 For a health system, particularly a system with a large, managed care patient population, 
patient retention is important to realize reductions in disease progression over time. The Markov 
model does not does not account for patient disenrollment, “churn” or other loss-to-follow-up 
aside from mortality. Future models should incorporate patient churn to provide health systems 
with a more accurate estimate of outcomes over time. Still, gains in LYs and QALYs are 
apparent sooner after DAA treatment, and Aim 2b model results show that treatment reduces 
HRU, thus near-term benefits to the health system from earlier treatment strategies may still be 
realized.  
 The Markov simulation model in Aim 3 focuses on effectiveness; many other studies 
using similar methods incorporate costs to conduct cost-effectiveness analyses (CEA) of 




most efficient use of health care resources. The SOC and strategies modeled, as well as the 
effectiveness results of this analysis are similar to other CEA studies. Further research should 
include health system costs of care to estimate more tailored cost-effectiveness measures.  
Aim 3 Conclusions 
 Aim 3 results have shown treating patients earlier can improve LYs and QALYs, 
as well as reduce HCV disease progression. Both patients and health systems can benefit from 
earlier treatment through reduced healthcare utilization. DAA treatments can effectively cure 
HCV;66,116 if more patients continue to receive DAA treatment, health systems have the potential 
to eradicate HCV infection entirely.23,24,184 
Dissertation Conclusion 
 This dissertation has shown that although the proportion of patients in a managed care 
setting who are tested and receiving treatment for HCV is improving, many may still experience 
obstacles to receiving treatment. Health disparities exist in preventing more patients from 
receiving DAA treatment (Aim 1). Patients that do receive DAA treatment are considerably more 
likely to achieve SVR (Aim 2a), reducing HRU for the health system (Aim 2b). SVR 
achievement also reduces HCV disease progression and improves patient quality of life (Aim 3). 
Continued improvements in HCV testing and treatment accessibility will further reduce disease 
progression and improve patient outcomes over time. 
 This dissertation has shown that policy efforts to increase HCV testing and 
treatment will be effective in reducing HCV disease burden. The analyses conducted here are 
based on patients diagnosed at the beginning of ACA expansion, as well as immediately prior to 
more efficacious, pan-genomic DAA treatments. Heath systems should continue to adopt broader 
testing efforts and employ mechanisms to reduce DAA costs to foster improvements in outcomes 
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APPENDIX A.  
Variables, level of measurement and method of identification for Aim 1. 
Variable Level of 
Measurement 
Method of Identification 
Exposure 
Index Date Date First HCV RNA+ lab result during the 
study period. See appendix B for a specific 
list of LOINC codes. 
Outcome   
Rx - First treatment exposure 
within 24 months of index date 
Dichotomous The most recent HCV antiviral dispensing 
<= 24 months following index date. “1” 
for dispensing, “0” otherwise. 
See appendices C-E for a specific list of 
drugs that constitute a treatment exposure. 
Baseline Clinical/Demographic Characteristics 
Gender Categorical “M” = male; “F” =female 
Race Categorical WH=White 
BA=African American 
AS=Asian 
OT=Other, Unknown, more than one race 
Ethnicity Categorical Y=Hispanic 
N=Non-Hispanic 
U=Unknown 
Age at Index Date Numeric Calculated from the difference between 
patient’s birth date and index date, divided 
by 365.25 







Liver Fibrosis (FIB-4) 
FIB-4 =((Age * AST_val) / 
(Plate_val * (sqrt (ALT_val 
)))) 
Continuous calculated results from most-recent AST 
and ALT lab results 
Obesity Dichotomous Defined as “1” or “0” for an ICD9/10 or 
BMI>= 30; 
ICD-9: 278.0x, v77.8, 649.1;  
ICD-10 E66* (except for E66.3); 
calculated from most recent available BMI 




Variable Level of 
Measurement 
Method of Identification 
Quan/Elixhauser Comorbidity 
Index136 
Continuous The total number of comorbid conditions 
identified during the 12-month baseline 
period, defined by SAS algorithm for ICD-
9/10 diagnosis codes 
Depression Dichotomous Defined as “1” or “0” for an ICD9/10; 






APPENDIX B.  
HCV Laboratory LOINC Codes 
NAME COMMON NAME LOINC CODE 
HCV RNA (PCR DETECTION LIMIT 
= 500 IU/ML) 
HCV RNA (PCR DETECTION 
LIMIT = 500 IU/ML) 
34703-9 
HCV RNA INTERPRETATION HCV RNA 59464-8 
HCV RNA LOG NUMBER (PCR) HCV RNA LOG NUMBER 
(PCR) 
49605-9 
HCV RNA, SER/PLAS, PCR HCV RNA SERPL PCR 38180-6 
HCV RNA, T-PCR DETECTION 
LIMIT <50 IU/ML 
HCV RNA SERPL T-PCR 34704-7 
HEP C RNA BDNA HEP C RNA SERPL BDNA 29609-5 
HEP C RNA, BDNA/TMA, 
QUANTITATIVE 
HEP C RNA, BDNA/TMA, 
QUANT 
48576-3 
HEP C RNA, PCR, QUAL HEP C RNA PCR QL 5012-0 
HEP C RNA, QN, PCR HCV RNA SER PCR QN 11011-4 
HEP C RNA, SERUM, PCR, QUAL HCV RNA SER PCR QL 11259-9 
HEP C RNA, SERUM, PROBE WITH 
TARGET AMPLIFICATION 
HCV RNA SER AMP QN 10676-5 
HEP C RNA, TISS, QL, PCR HEP C RNA, TISS QL, PCR 5011-2 
HEP C RNA, WHOLE BLOOD, PCR, 
QUAL 
HCV RNA WB PCR 5010-4 
HEP C VIRAL LOAD BDNA HCV RNA HPA 20571-6 
HEP C VIRUS RNA VIRAL LOAD 
PCR 
HCV RNA PCR QN 20416-4 
HEPATITIS C VIRUS IGG, IB HEP C IGG IB 33462-3 
HEPATITIS C VIRUS IGG,SER,QL HEP C IGG, SER QL 16129-9 
HEPATITIS C VIRUS IGG,SER,QN HEP C IGG, SER QN 16936-7 
HEPATITIS C VIRUS NS5 AB, IB HEP C NS5 AB IB 23871-7 
HEPATITIS C VIRUS RNA, LOG, 
SER/PLAS, SIGNAL AMPLIFIED 
PROBE 
HEPATITIS C VIRUS RNA, 
LOG, SER/PLAS, SIGNAL 
AMPLIFIED PROBE 
42617-1 
HEPATITIS C VIRUS RRNA,QL, 
NUCLEIC ACID PROBE 
HEP C RRNA QL, PROBE 6422-0 






APPENDIX C.  
Peginterferon NDCs 
GENERIC BRAND NDC 
PEGINTERFERON ALFA-2A PEGASYS 180MCG/0.5ML SYG 00004035239 
PEGINTERFERON ALFA-2A PEGASYS INJ 180MCG/M 00004035009 
PEGINTERFERON ALFA-2A PEGASYS INJ UD 00004035730 
PEGINTERFERON ALFA-2A PEGASYS KIT 180MCG/M 00004035039 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 120MCG 00085129701 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 120MCG 00085130401 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 150MCG 00085127901 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 150MCG 00085137001 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 50MCG 00085132301 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 50MCG 00085136801 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 80MCG 00085129101 
PEGINTERFERON ALFA-2B PEG-INTRON KIT 80MCG 00085131601 
PEGINTERFERON ALFA-2B PEG-INTRON REDIPEN PAK 4 KI 00085129702 
PEGINTERFERON ALFA-2B PEG-INTRON REDIPEN PAK 4 KI 00085131602 
PEGINTERFERON ALFA-2B PEG-INTRON REDIPEN PAK 4 KI 00085132302 
PEGINTERFERON ALFA-2B SYLATRON KIT 296MCG 00085138801 
PEGINTERFERON ALFA-2B SYLATRON KIT 444MCG 00085128702 





APPENDIX D.  
Ribavirin NDCs 
GENERIC BRAND NDC 
RIBAVIRIN VIRAZOLE INH 6GM UD 00187000714 
RIBAVIRIN (HEPATITIS C) COPEGUS TAB 200MG 00004008694 
RIBAVIRIN (HEPATITIS C) REBETOL CAP 200MG 00085119403 
RIBAVIRIN (HEPATITIS C) REBETOL CAP 200MG 00085132704 
RIBAVIRIN (HEPATITIS C) REBETOL CAP 200MG 00085135105 
RIBAVIRIN (HEPATITIS C) REBETOL CAP 200MG 00085138507 
RIBAVIRIN (HEPATITIS C) REBETOL SOL 40MG/ML 00085131801 
RIBAVIRIN (HEPATITIS C) RIBAPAK PAK 1000/DAY 49884007176 
RIBAVIRIN (HEPATITIS C) RIBAPAK PAK 1000/DAY 66435010699 
RIBAVIRIN (HEPATITIS C) RIBAPAK PAK 1200/DAY 49884034076 
RIBAVIRIN (HEPATITIS C) RIBAPAK PAK 1200/DAY 66435010799 
RIBAVIRIN (HEPATITIS C) RIBAPAK TAB 800/DAY 49884033876 
RIBAVIRIN (HEPATITIS C) RIBASPHERE TAB 400MG 66435010356 
RIBAVIRIN (HEPATITIS C) RIBASPHERE TAB 600MG 66435010456 
RIBAVIRIN (HEPATITIS C) RIBAVIRIN CAP 200MG 00781204304 
RIBAVIRIN (HEPATITIS C) RIBAVIRIN CAP 200MG 00781204316 
RIBAVIRIN (HEPATITIS C) RIBAVIRIN CAP 200MG 68382026012 
RIBAVIRIN (HEPATITIS C) RIBAVIRIN TAB 200MG 00093723281 
RIBAVIRIN (HEPATITIS C) RIBAVIRIN TAB 200MG 00406204616 






APPENDIX E.  
Primary Treatment Exposure Identifier NDCs 







RITONAVIR, AND DASABUVIR 
00074309328 






APPENDIX F.  
Outcome Measures 




Aim 1 First HCV antiviral 
prescription drug fill post 
index-date 






First HCV RNA- lab result 
post index-date; no detectable 
HCV RNA viral load in 
patient during 24-month 
follow-up period (defines 
cure) 
Dichotomous for any non-
detectable (defined by particular 
lab assay range) HCV RNA PCR 






Measure of patient usage of 
health care system. 
Emergency department (ED) 
or inpatient (IP) encounter 
during 24-month follow-up 
period 
Categorical, ED or IP encounters 
Incremental 
Effectiveness (IE) 
Aim 3 Difference in effectiveness 
(number of patients 
progressing through each 
disease state; as well as 
difference in total life years 
and Quality-adjusted Life 
Years, between each HCV 
disease progression state. 
Calculated as the difference in the 
proportion of patients for each 
HCV disease progression state 
(e.g. decompensated cirrhosis, 
hepatocellular carcinoma, liver 
transplant and mortality), as well 
as total life years and quality-
adjusted life years (QALYs) 
between each strategy and the 
SOC. Additionally, IE is 
calculated between strategies and 
previous strategies for each HCV 







APPENDIX G.  
Variables, level of measurement and method of identification for Aim 2a. 
Variable Level of Measurement Method of Identification 
Exposures 
Index Date Date First HCV RNA+ lab result during 
the study period. See appendix B for 
a specific list of LOINC codes. 
Rx - First treatment 
exposure within 24 
months of index date 
Time-varying by month 
following index date 
The most recent HCV antiviral 
dispensing <= 24 months following 
index date. “1” for dispensing, “0” 
otherwise. 
See appendices C-E for a specific list 
of drugs that constitute a treatment 
exposure. 
Outcome   
Sustained Virologic 
Response (SVR) 
Dichotomous for any 
non-detectable (defined 
by particular lab assay 
range) HCV RNA PCR 
lab result following 
index date 
First HCV RNA- lab result post 
index-date; no detectable HCV RNA 
viral load in patient during 24-month 
follow-up period (defines cure) 
Baseline Clinical/Demographic Characteristics 
Gender Categorical “M”= male; “F”=female 
Race Categorical WH=White 
BA=African American 
AS=Asian 
OT=Other, Unknown, more than one 
race 
Ethnicity Categorical Y=Hispanic 
N=Non-Hispanic 
U=Unknown 
Age at Index Date Numeric Calculated from the difference 
between patient’s birth date and 
index date, divided by 365.25 







No. Years Enrolled Prior 
to First HCV+ Date 
Continuous Count years between Index Date and 
earliest enrollment start date available 
for the patient 
Liver Fibrosis (FIB-4) Continuous calculated results from most-recent 




Variable Level of Measurement Method of Identification 
FIB-4 =((Age * AST_val) / 
(Plate_val * (sqrt 
(ALT_val )))) 
Obesity Dichotomous Defined as “1” or “0” for an ICD9/10 
or BMI>= 30; 
ICD-9: 278.0x, v77.8, 649.1;  
ICD-10 E66* (except for E66.3); 
calculated from most recent available 
BMI >= 30 during baseline period 
Quan/Elixhauser 
Comorbidity Index136 
Continuous The total number of comorbid 
conditions identified during the 12-
month baseline period, defined by 
SAS algorithm for ICD-9/10 
diagnosis codes 
Depression Dichotomous Defined as “1” or “0” for an 








APPENDIX H.  
Variables, level of measurement and method of identification for Aim 2b. 
Variable Level of 
Measurement 
Method of Identification 
Exposures 
Index Date Date First HCV RNA+ lab result during the 
study period. See appendix B for a specific 
list of LOINC codes. 
Rx - First treatment exposure 





The most recent HCV antiviral dispensing 
<= 24 months following index date. “1” 
for dispensing, “0” otherwise. 
See appendices C-E for a specific list of 
drugs that constitute a treatment exposure. 






First HCV RNA- lab result post index-
date; no detectable HCV RNA viral load 
in patient during 24-month follow-up 
period (defines cure) 
Outcome   
Healthcare resource 
utilization (HRU) 
Dichotomous Measure of patient usage of health care 
system. Emergency department (ED) or 
inpatient (IP) encounter during 24-month 
follow-up period. 
Baseline Clinical/Demographic Characteristics 
Gender Categorical “M”= male; “F”=female 
Race Categorical WH=White 
BA=African American 
AS=Asian 
OT=Other, Unknown, more than one race 
Ethnicity Categorical Y=Hispanic 
N=Non-Hispanic 
U=Unknown 
Age at Index Date Numeric Calculated from the difference between 
patient’s birth date and index date, divided 
by 365.25 







No. Years Enrolled Prior to 
First HCV+ Date 
Continuous Count years between Index Date and 
earliest enrollment start date available for 
the patient 
Liver Fibrosis (FIB-4) Continuous calculated results from most-recent AST 




Variable Level of 
Measurement 
Method of Identification 
FIB-4 =((Age * AST_val) / 
(Plate_val * (sqrt (ALT_val 
)))) 
Obesity Dichotomous Defined as “1” or “0” for an ICD9/10 or 
BMI>= 30; 
ICD-9: 278.0x, v77.8, 649.1;  
ICD-10 E66* (except for E66.3); 
calculated from most recent available BMI 
>= 30 during baseline period 
Quan/Elixhauser Comorbidity 
Index136 
Continuous The total number of comorbid conditions 
identified during the 12-month baseline 
period, defined by SAS algorithm for ICD-
9/10 diagnosis codes 
Depression Dichotomous Defined as “1” or “0” for an ICD9/10; 
296.2, 296.3, 296.5, 300.4, 309, 311 
 
